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ABSTRACT
A NOVEL ROLE FOR OSTEOPONTIN IN FACILITATING
WEST NILE VIRUS NEUROINVASION
by Amber M. Paul
May 2017
West Nile virus (WNV) is a positive-sensed, single-stranded RNA flavivirus that
can cause human neuroinvasive diseases, including encephalitis, meningitis, and flaccid
paralysis. The mechanisms by which WNV enters the central nervous system and the
host-factors that are involved in WNV-neuroinvasiveness are not completely understood.
Osteopontin (OPN), a multifunctional glycoprotein, has been implicated as a bio-marker
for a number of neuroinflammatory diseases. In particular, secreted (s)OPN has been
implicated to participate in recruitment of polymorphonuclear neutrophils (PMN) to sites
of its expression, while PMNs have been suggested to act as WNV reservoirs. Therefore,
sOPN recruitment of PMNs may contribute to neuroinvasive WNV infection via the
‘Trojan horse’ mechanism of viral entry into the brain. Therefore, we hypothesize braininfiltration of PMNs during neuroinvasive WNV pathogenesis is in part mediated by
sOPN. Our results show that sOPN expression was significantly increased in human sera,
human neuronal cells line, murine plasma, brain homogenates and primary neuronal
supernatant following WNV infection, indicating a role for OPN in WNV pathogenesis.
In addition, after challenge with WNV in vivo, Opn-/- mice exhibited a higher (70%)
survival rate than wild-type (WT) mice (30%). Consistent with this, qPCR analysis
between WT and Opn-/- mice demonstrated comparable levels of viremia; yet, reduced
viral burden in the brains of Opn-/- mice compared to WT controls. Analysis of brainii

infiltrating leukocytes displayed reduced PMNs and PMN-chemokine expression levels
in Opn-/- mice brains. Importantly, intracerebral supplement of recombinant OPN (rOPN)
into Opn-/- mice resulted in increased PMN-brain infiltration, increased viral load and
reduced overall survival. Together, these data suggest OPN facilitates WNV
neuroinvasion in a mouse model.

iii
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CHAPTER I - BACKGROUND
1.1 West Nile Virus Discovery and Epidemiology
West Nile virus (WNV) is a single-stranded (ss)RNA, arthropod-borne virus,
belonging to the family Flaviviridae. WNV was first isolated in Uganda, near the West
Nile district in 1937, from a female patient that presented febrile-like illness (Chancey,
Grinev, Volkova, & Rios, 2015). Since, it has spread to various countries within and
outside of Africa, causing serious public health concerns for many parts of the globe.
What was once endemic within tropical countries, has since spread to subtropical and
even temperate climates, primarily due to the spread of its primary vector the Culex
species of mosquito (Paz, 2015). The reasons for spread of this mosquito, and in such the
virus, are still not completely understood. Some reports have indicated global warming
climate changes, increased human-mosquito-bird habitat interaction, and/or fitness of the
mosquito and the virus (Paz, 2015).
From 1950-1980, mild WNV febrile-like illness cases were reported in the
countries of Israel, Egypt, India, France, and South Africa (Chancey et al., 2015; Paz,
2015). In 1957, the first neuroinvasive case of WNV was reported in Israel (Chancey et
al., 2015; Paz, 2015) and in the 1990s, a dramatic geographic spread of WNV throughout
the globe began to reach countries such as, Budapest (1996), Russia (1999) and the
United States (1999) (Chancey et al., 2015). The frequency and severity of the virus was
also developing, as neuroinvasive symptoms of encephalitis, meningitis, and flaccid
paralysis were becoming apparent. In the United States, it has spread to all States,
including other North American countries, such as Canada and Mexico (Paz, 2015).
Additionally, some South American countries and the vast majority of the Asian
1

continent have also reported WNV cases. It has been regarded as the most causative
agent of viral encephalitis (Chancey et al., 2015) and currently, there are no anti-viral
vaccines or therapeutics for WNV infection.
1.2 West Nile Virus Transmission
WNV is classified as a blood-borne virus, as it is transmitted via blood-to-blood
contact, primarily by the bite of an infected mosquito. WNV is also transmitted by human
blood transfusions and organ transplantations (Lanteri et al., 2014). However, the Centers
for Disease Control and Prevention (CDC) have instituted screening of donated blood
using nucleic-acid based testing (NAT’s), which have successfully prevented spread of
the virus (CDC, 2004). Additionally, although rare, transmission of the virus has also
been documented to occur from mother to baby through pregnancy, delivery or
breastfeeding (Hinckley, O'Leary, & Hayes, 2007). Mammalian species, including
humans and horses, are considered dead-end hosts of the virus, as the hosts immune
system can develop an adequate response to control the virus (Bowen & Nemeth, 2007).
However, avian species, are intermediate hosts and are unable to mount an effective
immune response against the virus, therefore are considered reservoirs for viral
amplification (Bowen & Nemeth, 2007). Not all avian species carry WNV, however,
some species such as the house sparrow, the American crow, and the American robin are
highly susceptible to WNV infection (Colpitts, Conway, Montgomery, & Fikrig, 2012).
Therefore, regions that are highly populated with these particular bird species are more
prone to increased frequencies of viral transmission (Brault, 2009). The primary vector
for transmission of WNV is the Culex mosquito; however, other species of mosquito have
been noted to carry WNV, including the Aedes species (Colpitts et al., 2012). In addition,
2

the virus can survive overwintering due to the process of vertical transmission between
female mosquitos and their eggs during oviposition (Baqar, Hayes, Murphy, & Watts,
1993). In brief, transmission of the virus is dependent on a variety of factors that enable
survival and success of the virus in endemic countries.
1.3 West Nile Virus Structure, Viral Genome, and Life Cycle
Structurally, WNV is approximately 50 nm in diameter and icosahedral in
symmetry. The virus has a multi-layered organization, including its outer membrane
containing the envelope and membrane proteins and an inner lipid membrane that
encompasses the viral genome, called the nucleocapsid, containing the structural capsid
protein (Chancey et al., 2015). WNV has a ssRNA genome with positive polarity, which
can be directly translated into a polyprotein. Its genome has approximately 11, 000 base
pairs, that contains one open reading frame (ORF) encoding a single polyprotein that is
subsequently cleaved by viral and host proteases. The viral genome also contains 5’ and
3’ untranslated regions (UTR), three structural genes, seven non-structural genes, and it is
devoid of a 3’ poly-adenylated tail, which makes it distinguishable from host RNA
(Brinton, 2014).
There are currently seven different WNV lineages that have evolved throughout
different regions of the globe, making WNV a genetically diverse virus. In addition to
their geographic differences, these different WNV lineages have evolved to cause more
human disease outbreaks, including lineages 1, 2 and 5 (Chancey et al., 2015; Ciota &
Kramer, 2013). For example, Lineage 1 clade (a) is the principle lineage of WNV that
caused the outbreak in North America in 1999 (Chancey et al., 2015).

3

At the cellular level, WNV binds to host membrane receptors and enters the cell
via receptor-mediated endocytosis. Proposed cellular membrane receptors include
integrins, which are highly expressed on neutrophils (Burg & Pillinger, 2001) and DCSIGN (Davis et al., 2006), which are dendritic cell-specific receptors. Through a pH
dependent process, the virus fuses its enveloped membrane with the host’s endosomal
membrane to uncoat its capsid containing the positive-sensed, ssRNA into the cytoplasm.
Here, the viral RNA genome is readily translated into functional proteins, such as RNAdependent RNA polymerase, and it directly copies itself into multiple negative-sensed
ssRNA stands to be used as templates for further positive-sensed ssRNA replication. At
the rough endoplasmic reticulum (ER) membrane, structural viral proteins and positivesensed ssRNA are assembled and packaged into infectious virions in the Golgi apparatus,
which are subsequently released from the cell via exocytosis (Suthar, Diamond, & Gale,
2013).
1.4 West Nile Virus Disease and Pathogenesis
Following inoculation within the skin, WNV actively replicates itself within skinresident dendritic cells (DC) called Langerhans cells. This initial infection triggers the
innate immune response to initiate an antiviral program, proinflammatory cytokines and
inflammatory mediators to inhibit the virus from replicating and secretes chemokines to
recruit leukocytes, such as neutrophils, to sites of infection to destroy the virus.
However, in some instances, the virus can successfully disseminate to secondary
lymphoid organs, including the lymph nodes and spleen where the virus is amplified
(Lazear & Diamond, 2014; Suthar et al., 2013).

4

Most human cases are asymptomatic (80%), while approximately 19% show
febrile illness-like symptoms and less than 1% of individuals develop severe neurological
illnesses, including meningitis, encephalitis and flaccid paralysis (Lazear & Diamond,
2014; Suthar et al., 2013). WNV is a neurotropic virus because it can actively infect
neurons within the central nervous system (CNS). Although the mechanisms of viral
entry into the CNS are not completely understood, three primary mechanisms have been
proposed; (a) Direct entry of the virus across the blood-brain barrier (BBB); (b)
retrograde transport of the virus via the peripheral nervous system (PNS); and/or (c) the
“Trojan horse” mechanism, whereby the virus hijacks immune cells to gain entry into the
CNS (Lazear & Diamond, 2014; Suthar et al., 2013).
Following infection, the innate and adaptive immune systems participate to
control infection. The antiviral immune response, via the generation of type I interferons
(IFNα and IFNβ), is initiated within the first few days of infection and is essential to
inhibit infection, as mice deficient in the type I IFN response are susceptible to viral
infection (Samuel & Diamond, 2005). Following antiviral initiation, innate immune cells
such as polymorphonuclear neutrophils (PMN), natural killer (NK) cells, macrophages,
and other granulocytes contribute to pathogen clearance through both cell intrinsic
mechanisms of phagocytosis and the release of enzymes and reactive oxygen species that
kill the virus. For instance, PMNs perform phagocytosis, degranulate and release
neutrophil extracellular traps (NETs) to kill invading pathogens (Kolaczkowska &
Kubes, 2013). While innate immunity is critical for rapid, non-specific killing of foreign
microbes, the adaptive immune system participates in generation of memory against the
foreign microbe, to rapidly control infection if encountered a second time. Adaptive
5

immune cells include CD4+ and CD8+ T cells and antibody-producing B cells. In terms of
viral infection, the adaptive immune response does not take full force until approximately
a week post infection. At this time cytotoxic CD8+ T cells and helper CD4+ T cells begin
to communicate with antigen presenting cells, such as macrophages and DCs that have
ingested and processed viral antigen in the context of major histocompatibility proteins I
or II (Vono et al., 2017). This interaction initiates the generation of antigen-specific
adaptive immunity and is the basis of producing T cells that can distinguish self- from
foreign- antigens. WNV infection in mice requires functional CD8+ cytotoxic T cells to
successfully control (Acharya et al., 2017) and clear the virus (Shrestha & Diamond,
2004). Therefore, proper participation with both the innate and adaptive immune
responses are necessary for effective control of WNV, while defects in any of these
pathways result in more severe infection and disease.
It is important to note that viral kinetics and disease pathogenesis is different
between human and mice. For instance, more than 80% of mice develop severe
neuroinvasive infection with 104-106 plaque-forming units (PFU) inoculation, which is
the infective dose identified during mosquito inoculation (Styer et al., 2007), however,
not all humans develop neurodisease. This may be due to different leukocyte population
percentages between humans and mice, the robustness of the immune responses
generated, the architecture of the blood brain barrier or many other physiological
differences between the two species (Mestas & Hughes, 2004; Suen, Prow, Hall, &
Bielefeldt-Ohmann, 2014). Nonetheless, control of viral infection in both species
involves specific commination with the innate and adaptive immune responses.

6

1.5 Innate Immune Mediators Against WNV
1.5.1 Pattern Recognition Receptors and Intracellular Antiviral Immune Mediators
Against WNV
WNV is an intracellular pathogen that is recognized by pattern recognition
receptors (PRRs) of the innate immune system. PRRs are essential mediators of the
innate immune response as they are responsible for distinguishing different pathogen- or
danger- associated molecular patterns (PAMPs or DAMPs) from self-antigens and
ultimately shape the adaptive immune response. Some notable PRRs include mannosebinding lectins (MBL) that are involved in the complement cascade, intracellular PRRs,
such as Retinoic inducible gene-1 (RIG-I), Melanoma differentiation-associated protein 5
(MDA-5) and NOD-like receptors (NLRs), including NALP3 and CIITA. Toll-like
receptors (TLR) are type I transmembrane PRRs that are located on the plasma
membrane and within endosomal membranes (Akira & Takeda, 2004; Chow, Franz, &
Kagan, 2015). TLRs are highly expressed on professional antigen presenting cells
(APCs), such as DCs. As mentioned DCs are one of the first cells infected by WNV
following skin-inoculation and in fact, most intracellular TLR pathways examined are
studied using DCs because these cells are involved in linking innate and adaptive
immunity, respond well against viral infections and highly express intracellular TLRs 3,
7, 8 and 9 (Lipscomb & Masten, 2002). Aside from APCs, other innate immune cells,
including PMNs, mast cells, eosinophils, and basophils all express TLRs, which are
necessary to quickly identify various molecular structures and engage immunity against
them. In addition, epithelial cells, fibroblasts, and endothelial cells express TLRs in order
to elicit their own form of non-specific, innate immunity. Collectively, all cells express
7

some ability to recognize self from non-self, suggesting the importance of PRRs in
restricting various PAMPS or DAMPs that can cause disease (Akira & Takeda, 2004).
TLR7 recognizes WNV, as Tlr7-/- mice have reduced survival and increased viral
load following WNV challenge (Town et al., 2009). In addition, TLR3 can also recognize
WNV, whereby TLR3 activation induced TNFα disruption of the BBB and initiated
WNV entry into the CNS (T. Wang, Town, Alexopoulou, et al., 2004). The latter report
highlights the importance of tightly restricted TLR activation, in order to induce
appropriate immune responses against foreign antigens while preventing non-specific
tissue damage. WNV signaling via TLRs initiates downstream adaptor proteins to work
together to regulate innate and antiviral immunity. Majority of TLR intracellular
signaling cascades merge onto the MyD88-dependent pathway, a pathway that is
important in controlling WNV infection, as MyD88-/- mice are highly susceptible to
WNV infection and neurons isolated from MyD88-/- mice have increased viral load
(Szretter et al., 2010). Interestingly, previous studies have indicated that intracellular
osteopontin (iOPN), physically associates with MyD88 following TLR9 and TLR7
stimulation with Herpes Simplex virus and following TLR7/9 ligation in plasmacytoid
DCs, activating the interferon response factor-7 (IRF-7) and transcription of IFNα (Cao
& Liu, 2006; Inoue & Shinohara, 2011; Shinohara et al., 2006). However, the association
between iOPN and WNV has not yet been studied.
In addition, IRF proteins can induce the expression of additional antiviral
proteins, including the interferon-induced tetratricopeptide repeat (IFIT) proteins. IFIT
proteins have been implicated in controlling WNV infection (Cho, Shrestha, Sen, &
Diamond, 2013; Daffis et al., 2010; Paul et al., 2016), Japanese Encephalitis virus
8

(Kimura et al., 2013) and vesicular stomatitis virus (Fensterl et al., 2012). IFIT proteins
are highly conserved among various species (Fensterl & Sen, 2014) and work in concert
to recognize and bind to the 5’-PPP end of viruses, host mRNA or to the translation
initiation factor eIF-3 to inhibit the initiation of viral/host protein translation (Fensterl &
Sen, 2014; Wacher et al., 2007). IFIT molecules have been instrumental in controlling
WNV infection, as Ifit2-/- mice are susceptible to WNV infection (Cho et al., 2013) and
Ifit1-/- neurons are highly permissive to WNV infection (Daffis et al., 2010). It has been
suggested that IFIT molecules may work in concert to inactivate viruses (Lazear &
Diamond, 2014), therefore understanding how multiple innate immune pathways
communicate is necessary to tailor specific antiviral therapeutics against WNV. In brief,
PRRs and downstream intracellular antiviral programs are important mediators of innate
immunity against WNV.
1.5.2 Cytokines, Chemokines and Inflammatory Mediators Against WNV
Following PRR engagement and intracellular signaling cascades, various
transcriptional programs are induced to produce copious amounts of cytokines,
chemokines, and inflammatory mediators in response to WNV infection. Some notable
cytokines that have been induced following WNV infection, including IL1β (Ramos et
al., 2012), IL-6 (Pena et al., 2014), TNFα (Shrestha, Zhang, Purtha, Klein, & Diamond,
2008), IL-12 (Town et al., 2009), IL-22 (P. Wang et al., 2012) and IL-23 (Town et al.,
2009). Generally, cytokines bind to their associated receptor on target cells to prompt a
functional output, which results in the destruction of the virus, apoptosis/necrosis of the
host cell, and/or cellular differentiation, which are all mechanisms that inhibit viral
amplification.
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The chemokines CXCL1 (Bai et al., 2010), CXCL2 (Bai et al., 2010), CXCL10
(Klein et al., 2005) and RANTES (Hussmann & Fredericksen, 2014) have also been
important innate immune mediators in the control of WNV. Chemokines play a
particularly important role in recruitment of leukocytes following infection to the sites of
their expression. Chemotaxis occurs via a concentration gradient and interestingly,
secreted osteopontin (sOPN), plays a vital role in neutrophil (Koh et al., 2007; J. Sodek,
Ganss, & McKee, 2000), dendritic cell (Weiss et al., 2001) and macrophage recruitment
(Giachelli & Steitz, 2000). However, sOPN expression following WNV infection has not
yet been studied.
In addition, inflammatory mediators, such as the complement receptor-1 (CR1)
(Mehlhop et al., 2005) and nitric oxide (Getts et al., 2012) are also induced following
WNV infection. Although in the peripheral immune system, inflammation is an
instrumental part of the innate immune response, the induction of overt inflammation in
the brain can cause detrimental effects on neurons causing neuropathy,
neurodegeneration and/or axonal transduction inhibition (Mrak, 2009). Indeed mice pretreated with anti-very late antigen (VLA)-4 integrin antibodies to inhibit the infiltration of
nitric oxide producing monocytes into the brain following WNV infection, resulted in
long-term survival of infected mice (Getts et al., 2012). While, macrophages treated with
aminoguanidine, mediated the inhibition of inducible nitric oxide synthase (iNOS) and
prolonged survival in WNV infected mice, suggesting nitric oxide plays a negative role
for neuroinflammation (Getts et al., 2012). In brief, innate immune mediator involvement
in WNV infection is critical, as it is necessary to control the virus, yet, bystander
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immunopathology is possible during neuroinvasive WNV-induced inflammation in the
CNS.
1.5.3 Innate Immune Cells and WNV
Recognition and clearance of WNV requires a tightly controlled activation
cascade, including the production of type I IFNs, proinflammatory cytokines,
inflammatory mediators, leukocyte-recruiting chemokines and the induction of
phagocytosis. As mentioned above, professional APCs, such as DCs, are among the first
innate immune cell type that encounters foreign or immunogenic self-molecules.
Recognition receptor engagement triggers these APCs to become rapidly activated to
elicit both an innate immune response and promote phagocytosis. Additionally, APCs can
shape the adaptive immune response by engaging antigen-specific cellular memory to
protect the host from future repeated exposure.
DCs have been studied extensively within the context of WNV infection, as they
are the principle cell type that first come into contact with the virus following skininoculation (Suthar et al., 2013) and WNV can preferentially bind to the DC-specific
cellular receptors called DC-SIGN (Martina et al., 2008). Interestingly, DC function has
also been linked to age, which is a determining factor in susceptibility to viral infection.
For instance, DCs cultured from older donors (approximate age 73 years) compared to
younger donors (approximate age 26 years) had reduced type I IFN production following
WNV infection in vitro (Qian et al., 2011). In addition, the significance of myeloid DCs
production of CXCL10 has been implicated as a biomarker for WNV susceptibility,
whereby reduced production of this chemokine resulted in higher prevalence for infection
(Qian et al., 2015).
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There are four main types of mature DCs; follicular DCs, lymphoid DCs, myeloid
DCs and plasmacytoid DCs, which are all capable of producing different innate immune
mediators in response to viral challenge (Lipscomb & Masten, 2002). Plasmacytoid DCs
(pDCs) are among the primary cells involved in active immunity against WNV infection,
as they can secrete copious amounts of type I IFN following infection, compared to
myeloid DCs (M. C. Silva, Guerrero-Plata, Gilfoy, Garofalo, & Mason, 2007). In healthy
adults, total DC populations comprise of approximately 0.46% of peripheral blood
leukocytes (Haller Hasskamp, Zapas, & Elias, 2005), therefore only a very small
proportion of these cells types are capable of producing a remarkable response against
viral infection, highlighting the importance of these cells in controlling viral infection.
Importantly, reactivation of circulating lymphocytes in the CNS by CD11c+ DCs were
instrumental in controlling viral infection, suggesting an additional role for DCs in the
brain (Durrant, Robinette, & Klein, 2013).
1.5.4 Neutrophils and WNV Persistence
Polymorphonuclear neutrophils (PMN) are classified as granulocytes because
they contain multiple granules/lysosomes that package antimicrobial proteins, proteases
and reactive oxygen species, which can deactivate pathogens via extracellular secretion
or during phagocytosis (Mayer-Scholl, Averhoff, & Zychlinsky, 2004). In addition, they
are one of the first cellular responders in the innate immune response against foreign
pathogens and are the most abundant immune cell in humans, as they constitute between
50-70% of white blood cells in circulation (Mocsai, 2013) and 10-25% in mice
circulation (Mestas & Hughes, 2004). In addition, the number of neutrophils present at
sites of infection has been shown to be essential in clearing infection (Zeidler,
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Germeshausen, Klein, & Welte, 2009). The lifespan of neutrophils in mice without
activation is 12 hours and when activated their lifespan increases seven-fold (Summers et
al., 2010), indicating a role for cellular persistence and possible bystander injury within
tissues where infection is present. The most unique feature of neutrophils is the release of
neutrophil extracellular traps (NETs). NETs are comprised of intracellular chromatin
DNA, histones, and granular proteins that actively immobilize pathogens, facilitate
phagocytosis of trapped pathogens and kill pathogens by way of antimicrobial histones
and proteases (Kolaczkowska & Kubes, 2013; Phillipson & Kubes, 2011).
The role of PMNs in WNV infection has been somewhat of a paradox, whereby a
previous study has shown that neutrophils can both respond against WNV challenge by
inducing phagocytosis and producing antimicrobial mediators, but are also capable of
serving as WNV reservoirs (Bai et al., 2010). In particular, when neutrophils were
depleted in mice prior to infection, they survived WNV challenge, however, when PMNs
were depleted post-infection this resulted in moribund mice, suggesting neutrophils also
protect mice from WNV infection (Bai et al., 2010). Therefore, PMNs are important
innate immune cells that respond to infection, yet they may play an important role in the
“Trojan horse” mechanism of WNV dissemination into the CNS.
Entry of PMNs into the brain parenchyma is termed leukocyte extravasation or
rolling-leukocyte transmigration, which requires several steps in order to anchor the
PMNs to the endothelial cells and promote transmigration of PMNs through tight
junctions. During PMN (leukocyte) extravasation three steps are performed; first rolling
of PMN is initiated by E-selectins on endothelial cells that are upregulated following a
stimulus, and bind to carbohydrate molecules on PMNs; second, chemokines bind to
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receptors on PMNs sending an activation signal that; three, induces a conformation
change in the integrins on the PMN to bind to cell adhesion molecules (CAMs) located
on the endothelium, promoting transendothelial migration of the PMN into the
parenchyma.
PMNs have multiple killing mechanisms, however why PMNs switch from a
defensive immune cell to a viral reservoir is an interesting question. A possible reason for
this is the immunosuppressive chemicals within mosquito vector saliva that is delivered
into the host during transmission, may inhibit PMN function. Indeed this is the case with
lymphocyte function and the yellow fever vector Aedes aegypti (Wasserman, Singh, &
Champagne, 2004), which is also a primary vector for WNV transmission. However, in
the laboratory, viral isolates inoculated in mice do not contain mosquito saliva, so this
may not be the principle cause of PMN immunosuppression in laboratory-based settings.
As mentioned above, the life span of PMNs increase when activated by cytokines, such
as TNF-α and IL-1β, while transmigration also supports PMN survival, by delaying
apoptosis though Akt activation (Elbim, Katsikis, & Estaquier, 2009; Pluskota, Soloviev,
Szpak, Weber, & Plow, 2008), therefore inflammatory conditions may paradoxically
contribute to PMN persistence as viral reservoirs. Additionally, PMNs acting as viral
reservoirs have been implicated in other viral infection, such as H5N1 influenza (Gu et
al., 2007; Hartshorn et al., 1995) and Epstein-Barr Viral (EBV) infections (Drescher &
Bai, 2013; Gosselin et al., 1991; Savard & Gosselin, 2006). In one report, H5N1
influenza was shown to directly decrease the function of PMNs and monocytes by
binding the viral surface protein hemagglutinin to the host sialic acid bearing surface
receptors CD43 and CD45. This interaction cross-linked these receptors, deactivating the
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oxidative burst responses of PMNs and monocytes (Hartshorn et al., 1995). Briefly, viral
interaction with host-cell mediators can immunomodulate the function of PMNs through
prevention of apoptosis and promotion of cellular persistence (Elbim et al., 2009);
therefore, the role of PMNs as viral reservoirs during WNV pathogenesis is possible.
In line with this, human WNV cases with neurological impairment, have
exhibited neutrophilia in their cerebral spinal fluid (CSF), indicating a possible role for
PMNs in the development of the neurological symptoms of WNV infection (Crichlow,
Bailey, & Gardner, 2004; Tyler, Pape, Goody, Corkill, & Kleinschmidt-DeMasters,
2006). Moreover, IL-22 has been shown to be an important molecule in facilitating PMN
recruitment during WNV infection, as Il-22-/- mice had defective PMN migration into the
brain and were more resistant to WNV infection (Wang et al., 2012). In brief, PMNs have
been implicated to play a potential role in neuroinvasive WNV infection in humans,
whether acting in favor of the virus or the host remains elusive.
1.6 The Central Nervous System and West Nile virus
1.6.1 WNV Neuroinvasive Infection and Mechanisms of Viral Entry into the Brain
WNV causes neuroinvasive symptoms in a small percentage (<1%) of infected
individual, however the root cause for neuroinvasiveness that is observed in some
patients but not others is still not completely understood. Deficits in the interferon
response has been described to play a potential role (Cho & Diamond, 2012). However,
another overlooked possibility may be that chronic inflammatory conditions, which are
notable within the elderly (the most at risk for infection), may contribute to age-related
disease and has recently been termed inflammaging (Franceschi & Campisi, 2014). Lowgrade inflammation has been linked to immune senescence, neuronal dysfunction and
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changes in body composition (Franceschi & Campisi, 2014), such as in blood-brain
barrier integrity (Elahy et al., 2015). During inflammaging cytokines including IL-6 and
TNF-α, which can contribute to BBB disruption, are slightly increased (Franceschi &
Campisi, 2014) and consistent, low-grade immune stimulation with these
proinflammatory cytokines can lead to immune senescence (Deeks, 2011), leaving the
host susceptible to WNV. In addition, differential immune cell profiles have been
identified between WNV fever and neuroinvasive patients. Some reports have identified
that although immune compromised individuals’ have poor viral control and higher
potential of neuroinvasiveness (Diamond et al., 2003; Kumar, Belcaid, & Nerurkar, 2016;
Samuel & Diamond, 2005), there is also the potential for immune-mediated damage
causing neurological symptoms. For instance, blood collected from neuroinvasive
patients had higher numbers of WNV-responsive cells (CXCR3+CCR4+CCR6-T cells)
with more potent responses (IFNγ production) and reduced immune suppressive (Treg)
cell populations, suggesting uncontrolled immunity against WNV is present in
neuroinvasive WNV infections (James et al., 2016).
Furthermore, different strains of WNV may also contribute to neuroinvasiveness
(Lanciotti et al., 2002). For instance, NY99 (pathogenic) and WNV Eg101 (nonpathogenic) stains displayed differential host gene expressions, resulting in increased IL1β and CXCL1 expression following infection with the NY99 pathogenic strain of WNV,
but not with WNV Eg101 non-pathogenic infection (Kumar et al., 2016), suggesting
unchecked inflammation can contribute to pathogenicity. Adding complexity to this,
although induction of unchecked inflammation following infection appears to contribute
to pathogenicity, for example increased Il-1β and TNF-α, both of these proinflammatory
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mediators have also been described to be necessary to protect mice from WNV by
promoting immune trafficking into the brain to control infection (Ramos et al., 2012;
Shrestha et al., 2008). Therefore, although the immune response is necessary to clear
infection in the brain, it is well-accepted that perturbed, prolonged and robust immune
cell trafficking into the brain can also be detrimental to brain architecture through
bystander damage (Aarli, 1983; Getts et al., 2012; Varatharaj & Galea, 2017),
(Sankowski, Mader, & Valdes-Ferrer, 2015). Therefore, proper WNV immunity must be
tightly regulated to only control infection, without causing bystander damage and
minimize pathogenic responses, while timing of immune cell infiltration into the brain
following WNV infection may also be important to consider. The best example of this is
in relation to previous work with PMNs as viral reservoirs, as PMNs depleted from mice
prior to WNV infection resulted in better survival, while depletion of PMN post-WNV
infection resulted in rapid morbidity (Bai et al., 2010). These results not only identified
an important immune cell type that is responsible for WNV clearance in the brain but
also provided insight into the persistence of WNV within PMNs, acting as viral
reservoirs.
As described above, there are three main mechanisms for WNV entry into the
CNS; (a) direct entry of the virus across the BBB, albeit through tight junctions or
through direct infection of endothelial cells, termed the hematogenous route (Suen et al.,
2014); (b) axonal retrograde transport of the virus via the PNS (Samuel, Wang,
Siddharthan, Morrey, & Diamond, 2007); and/or (c) the “Trojan horse” mechanism,
whereby the virus hijacks immune cells to gain entry into the CNS (Lazear & Diamond,
2014; Suthar et al., 2013) (Diamond & Klein, 2004; Garcia-Tapia, Loiacono, &
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Kleiboeker, 2006; Hunsperger & Roehrig, 2006; Kramer-Hammerle, Rothenaigner,
Wolff, Bell, & Brack-Werner, 2005; Monath, Cropp, & Harrison, 1983; Samuel &
Diamond, 2006; Samuel et al., 2007; Suen et al., 2014; Verma et al., 2009). As
mentioned above, lamins and DC-SIGN are two types of receptors that promote WNV
infection of cells. Other host receptors on endothelial cells including glycoaminoglycans
(GAGs) or c-type lectins can also permit infection, which enables viral entry into the
brain parenchyma. For instance, attenuation of GAG expression in mice have reduced
BBB invasion of group B streptococcus (Chang et al., 2011). Aside from viral entry
through direct infection of endothelial cells, the BBB is designed to only allow small
molecules less than 1 nm in diameter (Jain, 2012). WNV has a diameter of 50 nm and
therefore a disrupted BBB vasculature would be required for viral entry between
endothelial cells. Another mechanism of viral entry into the CNS is via the peripheral
nervous system (Samuel et al., 2007). In this model of infection, peripheral WNV infects
axons of the PNS near the site of viral inoculation and retrograde transports the PNS into
the CNS (Samuel et al., 2007).
The third and most relevant to this study is the Trojan horse mechanism of viral
entry, which is considered a “second wave” of viral entry (Roe et al., 2012) because
inflammation in response to WNV establishment in the brain precedes recruitment of
leukocytes to clear infection. As mentioned, PMNs have been identified as major carriers
of WNV (Bai et al., 2010), while infected T cells and macrophages have also been
identified to harbor WNV into the CNS (Cardosa, Porterfield, & Gordon, 1983; Samuel
& Diamond, 2006; Wang et al., 2008), albeit at much lower levels than PMNs (Wang,
Town, Alexopoulou, et al., 2004). Leukocyte recruitment is mediated through induction
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of endothelial cell surface proteins, such as ICAM and VCAM that initiate leukocyte
extravasation into the CNS (Roe, Orillo, & Verma, 2014) and development of
inflammatory cytokines that promote BBB permeability (Roe et al., 2012). The adherence
proteins ICAM-1, VCAM-1, and E-selectin are all involved in PMN extravasation and
are induced in human brain microvasculature following WNV infection (Roe et al.,
2014). In addition, reduced tight junction proteins, between endothelial cells can
contribute to WNV disease severity (Roe et al., 2012). For example, tight junction
proteins ZO-1, Occuldin, JAM-1 and Claudin-1 showed reduced expression following
WNV starting at day 4 post-infection, while leukocyte infiltration was observed in brains
at day 8 p.i. (Roe et al., 2012), suggesting expression of tight junction proteins are also
necessary to prevent WNV Trojan horse entry of leukocytes, which can contribute to
neurodisease.
1.6.2 CNS Resident Cells and WNV Infection
Under non-pathogenic conditions, a robust and activated immune system is absent
in the nervous system primarily because presence of high numbers of activated immune
cells could cause detrimental effects by way of bystander brain tissue damage (Aarli,
1983; Getts et al., 2012). Unchecked neuroinflammation as a results of atypical, active
immune cell infiltration in the brain occurs in many neuroinflammatory diseases, such as
multiple sclerosis and Alzheimer’s disease (Comi et al., 2010; Shimizu et al., 2013),
while regulated, steady state leukocytes in the brain can also contribute to repair and
healing (Schwartz, Kipnis, Rivest, & Prat, 2013). Indeed the brain is in constant
surveillance and in communication with the immune and circulatory systems (Shimada &
Hasegawa-Ishii, 2017), however the CNS has also adapted its own immune strategy
19

within CNS-resident cells (Hanamsagar, Hanke, & Kielian, 2012; Lampron, Elali, &
Rivest, 2013; Ransohoff & Brown, 2012) through microglia and astrocytes. Both of these
brain-resident immune cells derive from the myeloid cell lineage (similar to
macrophages) and function to survey the CNS for foreign microbes and respond to
infection by producing inflammatory mediators, cytokines and chemokines (Giulian,
Baker, Shih, & Lachman, 1986; Hayes, Woodroofe, & Cuzner, 1988; Zucker-Franklin,
Warfel, Grusky, Frangione, & Teitel, 1987). In line with this, CNS diseases are possible
if microglia responses are not tightly regulated (Czirr & Wyss-Coray, 2012; Ransohoff &
Brown, 2012). For instance, lipopolysaccharide (LPS) and IFNγ primed macrophages and
microglia can induce the similar levels of nitric oxide (NO) at 48 and 74 hour post
activation (Brantley et al., 2010) and produce similar cytotoxic response against tumor
cells (Eue, Kumar, Dong, Killion, & Fidler, 1998), suggesting bystander tissue damage is
possible within the CNS through brain-resident immune cell activation in the absence of
peripheral leukocyte infiltration. It has also been described that, although a mechanism
for immunity is present in the brain, these responses are not capable of clearing infection
alone and must recruit circulating immune cells for aid (Schwartz et al., 2013), therefore
communication between the brain and the circulatory and immune systems are highly
interconnected.
Neurons can express TLRs on their surface and within endosomal compartments
(Lee, Lee, Cho, & Lee, 2013); therefore, they possess the ability to recognize and
respond to WNV challenge. Antiviral mechanisms in neurons are in place to inhibit viral
replication, for example, IL1β and IFNγ have been described to synergize within neurons
to inhibit WNV replication (Ramos et al., 2012). As mentioned above, IFIT molecules
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within the CNS, in particular within neurons, play an important role in controlling WNV
infection (Cho et al., 2013; Daffis et al., 2010); therefore, antiviral programs are initiated
following WNV challenge. In line with this study, cortical neurons were found to be the
most prominent producers of OPN in HIV-associated neurocognitive disorders, compared
to microglia and astrocytes (Silva et al., 2015). However, the role for OPN production in
WNV neuroinflammation has not yet been studied. WNV is classified as a neurotropic
virus that can cause both direct neuronal damage via induction of CNS-intrinsic
mediators and indirect neuronal damage via infiltrating immune cell production of innate
immune mediators. Acute and chronic inflammation can lead to long-term
neuropathological effects including flaccid paralysis, neuropathy, chronic fatigue, and/or
possible life-threatening clinical symptoms. Therefore, understanding WNV
neuropathology is of critical importance, not only to inhibit viral transmission but also to
develop new therapeutics against WNV-induced neurodisease.
1.6.3 Disruption of the Blood-Brain Barrier
The brain was previously thought to be an immune privileged organ, primarily
because grafting tissue in the brain results in prolonged tissue survival in comparison to
grafting outside of the brain (Shimada & Hasegawa-Ishii, 2017). Since it has been
identified that the brain is not immune privileged, communication between the immune
system and the CNS is constant (Shimada & Hasegawa-Ishii, 2017). Very recently, a
lymphatic system has been identified in the brain and functions to drain interstitial fluid
and provide immune surveillance (Iliff, Goldman, & Nedergaard, 2015). Another
communication interface between the peripheral immune system and the CNS is via the
BBB, which serves as an interface between the circulatory system and brain parenchymal
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cells (Shimada & Hasegawa-Ishii, 2017). The BBB consists of blood vessels that are
comprised of endothelial cells interconnected with transmembrane tight junction proteins
such as, occludins and claudins, which are linked to adaptor proteins anchored to actin
filaments, called zo-1. There are also additional adherens junction proteins, such as
cadherins that are linked to cytoskeleton catenins (Larochelle, Alvarez, & Prat, 2011).
Surrounding these cells includes the endothelial basement membrane, contractile cells
called pericytes and the parenchymal basement membrane, which directly communicates
with astrocytic endfeet within the brain (Sofroniew, 2015).
The main function of this highly organized barrier is to prevent neurotoxic
compounds from entering the brain parenchyma (Alyautdin, Khalin, Nafeeza, Haron, &
Kuznetsov, 2014) and is designed to prevent passage of materials that are greater than 1
nm is size (Jain, 2012). Indeed, nanomedicine therapeutics struggle to determine how to
transport molecules across the BBB, while literature in this field is of great importance to
study BBB architecture. It has been describe that although permissive to molecules less
than 1 nm in size, additional factors such as receptor anchoring and hydrophobicity play a
role in transport of molecules across the BBB (Jain, 2012; Siegel, 1999). This would
account for the neuroinvasive potential of WNV (50 nm in diameter) early in infection,
which can bind to GAGs, c-type lectins and laminins that are expressed on endothelial
cell surfaces (Perera-Lecoin, Meertens, Carnec, & Amara, 2013) in the absence of BBB
compromise. On the other hand, leukocytes (7-30 μm in diameter) gain access into the
brain following receptor anchorage that is observed during immune cell extravasation
only after inflammation induces expression of these proteins on the surface of endothelial
cells. Therefore, under normal conditions, circulating immune system cells have limited
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access into the brain, while under disease conditions; immune cells are recruited into the
brain, through leukocyte extravasation with the goal of clearing toxic mediators.
However, timing and duration of immune cell infiltration is key to preventing aberrant
responses. For example, GFP-tagged peripheral monocyte-derived macrophages in mouse
spinal cord injury showed delayed entry and enhanced clearing potential following BBB
breached-injury, while they were not detected in non-lesion spinal cords (Shechter et al.,
2009). Therefore, highlighting the precise regulation of immune “intensity”, i.e. via the
level of proinflammatory mediators produced, leukocyte extravasation timing and the
type of infiltrating leukocytes distinguishes healthy from compromised BBBs.
Indeed the BBB is vulnerable to proinflammatory mediators, such as NO and
matrix metalloproteinases (MMPs) (Kempuraj et al., 2016; Larochelle et al., 2011; Zhang
et al., 2015), and following WNV infection brain-resident cells produce TNF-α and IL-6
(Kumar, Verma, & Nerurkar, 2010; Pena et al., 2014). As a mechanism of viral entry,
penetration of WNV into the CNS is associated with a transient increase of BBB
permeability, suggesting WNV enters the brain initially through the hematogenous route
(Wang, Town, Alexoupoulou, et al., 2004). Other molecules such as TNF- receptor-1
and ICAM-1 are required for BBB permeabilization following WNV infection (Dai,
Wang, Bai, Town, & Fikrig, 2008; Wang et al., 2008; Wang, Town, Alexoupoulou et al.,
2004), therefore many different mechanisms are engaged following WNV infection and
BBB disruption, resulting in immune cell extravasation into the brain parenchyma.
Therefore, controlled immune surveillance and regulated inflammation during viral
infection is indispensable to prevent neurodegeneration (Kempuraj et al., 2016).
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1.7 Osteopontin
1.7.1 Intracellular Osteopontin
Osteopontin (OPN) is a negatively charged, glycoprotein originally named for its
origin within bone, in particular for its expression within osteoclasts and osteoblasts
(Butler, 1989; Oldberg, Franzen, & Heinegard, 1986). It was first described by Hynes and
colleagues, as a phosphorylated protein that is secreted from transformed cells (Senger,
Wirth, & Hynes, 1979). OPN has been implicated in a variety of cellular processes
including bone remodeling, tumorigenesis and immune cell chemotaxis (Sodek et al.,
2000). OPN is secreted by cells of the immune system, such as activated T cells and has
also been called early T-lymphocyte activation 1 (Eta-1) (Patarca et al., 1989; Wang &
Denhardt, 2008). This multifaceted protein has been induced in different neurological
pathologies, including multiple sclerosis (Shimizu et al., 2013), Alzheimer’s disease
(Comi et al., 2010), frontotemporal dementia (Mattsson et al., 2008), HIV-associated
dementia (Brown et al., 2011; Burdo, Ellis, & Fox, 2008), malignant gliomas (Lu et al.,
2012) and brain tumor associated metastases (Weber & Ashkar, 2000). However, the role
of OPN during WNV infection has not yet been studied.
There are two isoforms of OPN, one is expressed exclusively inside cells
downstream of the TLR7/9 signaling cascade, called intracellular OPN (iOPN), which
lacks a 16 amino acid signal sequence, targeting OPN to the cytoplasm and not the Golgi
(Shinohara, Kim, Kim, Garcia, & Cantor, 2008). Initial identification of iOPN was a
result of two primary observations; one, treatment with recombinant (r)OPN in Opn-/mice did not always reverse the phenotypes, and two, OPN depletion with antibodies in
WT mice did not always reproduce Opn-/- phenotypes, suggesting an intracellular role for
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OPN (Bourassa, Monaghan, & Rittling, 2004; Sato et al., 2008; Shinohara et al., 2006;
Zhu et al., 2004). Its expression is cell-specific, as APCs for example, produce high
levels of iOPN compared to T cells (Cantor & Shinohara, 2009). The expression of iOPN
is also involved in cytoskeletal rearrangements (Zhu et al., 2004) and has been a major
area for cancer research, as it has been actively involved in uncontrolled proliferation of
tumor cells (Bourassa et al., 2004). However, the role for iOPN has yet to be elucidated
during WNV infection.
1.7.2 Secreted Osteopontin
The other isoform is full-length, secreted OPN (sOPN) (Shinohara et al., 2008;
Zhao et al., 2010), which contains a 16 amino acid signal sequence that targets sOPN to
the Golgi for packaging and secretion out of the cell (Sodek et al., 2000). sOPN
participates in leukocyte recruitment (Ashkar et al., 2000), DC emigration to lymph
nodes from the epidermis (Weiss et al., 2001) and recruitment of PMNs to sites of its
expression (Koh et al., 2007; Sodek et al., 2000). In line with this, previous literature has
indicated reduced PMN extravasation and tissue injury is observed in Opn-/- mouse
models of hepatic disease (Yang et al., 2014) and OPN expression precedes innate
immune cell infiltration in mouse models of hepatic disease (Diao et al., 2004). While,
following myocardial infarction OPN is induced resulting in increased migration of
PMNs and monocytes into the infarct tissue (Singh, Foster, Dalal, & Singh, 2010).
Moreover, a recent report has indicated that inflammatory cells infiltrated into the CNS in
response to OPN expression and caused localized inflammation following i.p. injection of
pertussis toxin (Marcondes et al., 2014). This migration was a result of increased
expression of the OPN receptor CD44v6 on peripheral immune cells (Marcondes et al.,
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2014). In line with this, PMNs can express high levels of CD44 (Takazoe et al., 2000)
and the integrin receptor αvβ3, both of which are important for neutrophil migration in
transepithelial migration across the intestinal epithelium in human intestinal epithelial
cells (Brazil et al., 2013; Kim, Skokos, Myer, Agaba, & Gonzalez, 2014); suggesting not
only does increased sOPN, but increased PMN cell receptors for OPN binding, results in
PMN migration.
1.7.3 Osteopontin in Central Nervous System Diseases
OPN expression within the CNS has been linked to disease development. As
mentioned above, OPN has been induced in many different neurological pathologies,
including multiple sclerosis (Shimizu et al., 2013), Alzheimer’s disease (Comi et al.,
2010), frontotemporal dementia (Mattsson et al., 2008), HIV-associated dementia
(Brown et al., 2011; Burdo et al., 2008), malignant gliomas (Lu et al., 2012) and brain
tumor associated metastases (Weber & Ashkar, 2000). During multiple sclerosis (MS),
OPN expression is linked to the severity of the disease, secondary progressive patients
had significantly higher OPN expression compared to relapsing-remitting MS patients in
plasma (Shimizu et al., 2013). During MS pathogenesis myelin-reactive T-cells infiltrate
into the CNS and cause neuroinflammation and ensuing neurodegeneration and since
increased OPN is found in more severe cases, sOPN may be a major contributor to
increased brain-infiltrating, reactive leukocytes in MS pathogenesis. Alzheimer’s disease
(AD) is another neuropathological disease that has indicated a role for OPN, whereby AD
patients have increased OPN expression in their CSF early in disease progression (Comi
et al., 2010). It has also been suggested that PMNs migrate toward amyloid plaques in a
mouse model of AD and upon arrival, they accumulate and create senile plaques, which
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are implicated in pathophysiology of AD (Baik et al., 2014). Therefore, after initial Aβ
plaque deposition ensues in the brain, innate immune cells (i.e. PMNs) migrate into the
brain to non-specifically clear the underlying condition, however, can paradoxically
cause bystander inflammation and tissue destruction, increasing disease progression. This
may also occur during WNV neuroinvasion, whereby innate immune cells traffic into the
brain to clear infection, yet carry more virus into the brain, contributing to increased
inflammation and neuronal death. In addition, frontotemporal dementia has been
described as a progressive, neuropathological disease that is characterized by axonal
degeneration and induced OPN expression, that is only induced during rapid progression
of disease (Mattsson et al., 2008). In brain tumor models, OPN involvement has been
implicated as a prognostic biomarker, as it has been associated with metastatic brain
tumors and malignant gliomas. In one report, application of rOPN enhanced migration of
glioma cells and the expression of heme oxygenase (HO)-1, by signaling the transcription
factor Nrf-2, downstream the ERK and Akt signaling pathways (Lu et al., 2012). In
addition, ERK, Akt and HO-1 inhibitors reduced cellular migration of glioma cells in
brain metastasis. Therefore, sOPN can act on OPN receptors to activate downstream ERK
and Akt signaling pathways to promote the translocation of the transcriptional promoter
Nrf-2 and subsequent HO-1 production (Lu et al., 2012). Furthermore, CD44v6 receptors
work through the Akt pathway of activation (Herishanu et al., 2011) that is involved in
cellular migration and proliferation, which may be the cause of increased PMN survival
during neuroinvasive WNV infection. In brief, understanding the role of OPN within the
brain, along with the peripheral immune system is critical and may serve as an important
target to prevent neurological disorders.
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1.7.4 Osteopontin in Central Nervous System and Non-Central Nervous System
Viral Infections
OPN expression has also been linked to viral-related pathologies. For instance,
Dengue virus, another arthropod-borne virus, showed marked increase in sOPN and
iOPN in plasma isolated from first-time infected Dengue fever and dengue hemorrhagic
fever patients (Chagan-Yasutan et al., 2014). OPN levels were only observed during the
critical phase of infection (day 4-5), when symptoms are most severe, while reduced
OPN expression was observed in the recovery phase (day 7-8) of infection, suggesting an
important role for this protein in response to acute infection. Chronic hepatitis B virus
(HBV) causes liver disease and hepatocellular carcinoma and marked increase in sOPN
expression has been reported in plasma isolated from hepatocellular carcinoma patients,
as well as is a prognostic biomarker for the development of the disease following HBV
infection (da Costa et al., 2015). Moreover, hepatitis C virus (HCV) also induces chronic
liver injury and disease and increased sOPN expression was observed in the liver and
serum of patients infected with chronic HCV (Choi et al., 2014). In this report, treatment
of Huh7.5 cells with sOPN resulted in increased HCV replication, while neutralizing
sOPN with OPN specific aptamers repressed HCV levels (Choi et al., 2014). Respiratory
syncytial virus (RSV) infection in mice was shown to induce OPN expression after
intranasal inoculation and studies with older (19-21 months) versus younger (2-3 months)
mice displayed expression of sOPN was delayed but prolonged in older mice, which are
more susceptible to RSV infection (Wong et al., 2014). In addition, human T-cell
lymphotropic virus type-1 (HTLV-1) infection results in neuroinflammatory disease that
is associated with CD4+ T cell infiltration into the CNS and myelopathy/tropical spastic
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paraparesis (M/TSP) and increased sOPN, IL-17 and IL-22 expression were observed in
M/TSP patients but not asymptomatic carriers of HTLV-1 (Sarkis et al., 2013). These
results further suggest other factors independent of the virus (i.e. immune cell infiltration
into the brain), contribute to neurological disease symptoms observed in HTLV-1
infections. Moreover, elevated OPN levels in the brain and plasma of simian
immunodeficiency virus (SIV) infected macaques, along with increased CD44v6 receptor
expression within monocytes, positively correlated with viral-induced CNS disease
(Brown, 2012). Additionally, OPN is elevated in the brain, CSF and plasma of patients
with human immunodeficiency virus (HIV)-associated dementia (Burdo et al., 2008).
Interestingly, HIV-infection induced OPN in brain tissue and CSF, yet HIV-associated
dementia patients exhibited OPN induction in plasma, as well as in the brain and CSF
(Burdo et al., 2008), suggesting multi-organ involvement for sOPN may contribute to
disease progression.
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CHAPTER II – SIGNIFICANCE & HYPOTHESIS
2.1 Significance of the Study
West Nile virus (WNV) is a neurotropic virus that can cause encephalitis,
meningitis, flaccid paralysis and/or possible death in humans. Recent clinical disease case
data indicates 56% of all WNV reported cases in the United States in 2016 were
neuroinvasive (1,140 / 2,038) (CDC, 2017), therefore controlling neuroinvasive WNV
infection is of critical importance.
Understanding the mechanisms involved in the hosts’ innate immune response
against WNV are necessary to control viral-induced neuropathogenesis. It is well
established that unchecked, aberrant or chronic inflammation leads to bystander tissue
damage, which becomes of particular concern in relation to the CNS (Kempuraj et al.,
2016; Ransohoff, 2016). The antiviral chemokine OPN, has a dual role in innate
immunity, whereby intracellular OPN (iOPN) is involved in the production of type I IFNs
and secreted OPN (sOPN) is a potent chemokine that recruits dendritic cells (DC) (Weiss
et al., 2001) and polymorphonuclear neutrophils (PMN) (Koh et al., 2007; Sodek et al.,
2000) to sites of its expression, preceded by viral infection (Roe et al., 2012).
Additionally, sOPN induction has been observed in multiple CNS-viral infections
(Chimparlee et al., 2015; Choi et al., 2014; Silva et al., 2015) and is robustly induced in
neurons following infection with HIV (Silva et al., 2015). Therefore, early OPN
expression following infection is instrumental in generating immunity within the CNS,
however prolonged OPN may contribute to aberrant inflammation. Moreover, since
sOPN can recruit leukocytes to sites of its expression, it may play a role in the Trojan
horse mechanism of WNV entry. In brief, the focus of this dissertation is to identify the
30

mechanisms involved during neuroinvasive WNV and the role that OPN plays in this
process.
2.2 Hypothesis
Understanding the immune mechanisms against WNV is critically important to
control WNV-induced neurodisease. Innate immune responses against WNV include,
recognition of the virus via various PRRs within both the PNS and the CNS, induction of
intracellular signaling cascades that produce cell-intrinsic molecules to directly inhibit
WNV and soluble extracellular proteins to recruit leukocytes to aid in the defense against
the virus (Lazear & Diamond, 2014; Suthar et al., 2013). Importantly, it is only after
CNS-infection or injury is established in the brain that peripheral immune cells traffic
into the brain with hope to clear the underlying problem (Wilson, Weninger, & Hunter,
2010), which has been suggested to be the case in neuroinvasive WNV infection (Roe et
al., 2012). First, WNV establishes itself within neurons, as it is a neurotropic virus, prior
to the induction of various chemokines, disruption of tight junction proteins and
induction of leukocyte extravasation markers, which then recruits innate immune cells
into the brain to clear the virus (Roe et al., 2012). However, when immune cells traffic
into the brain they may be carrying virus, as proposed by the ‘Trojan horse’ mechanism
of WNV neuroinvasion (Suthar et al., 2013); paradoxically contributing to viral
pathogenesis.
OPN is a multifaceted protein that participates in the intracellular innate antiviral
program as it is involved in the amplification of type I IFNs in plasmacytoid DCs (Cao &
Liu, 2006; Inoue & Shinohara, 2011). It also works as a secreted chemokine to recruit
various leukocytes such as DCs (Weiss et al., 2001) and PMNs (Koh et al., 2007) to sites
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of its expression. PMNs are important cells involved in innate immunity as they are the
first responder to sites of infection and the most abundant leukocyte in the human
immune system. However, they have also been described as viral reservoirs for WNV
(Bai et al., 2010). sOPN has been implicated in many different CNS pathologies,
including multiple sclerosis (Shimizu et al., 2013), Alzheimer’s disease (Comi et al.,
2010), frontotemporal dementia (Mattsson et al., 2008), HIV-associated dementia
(Brown et al., 2011; Burdo et al., 2008), malignant gliomas (Lu et al., 2012) and brain
tumor associated metastases (Weber & Ashkar, 2000). From these reports, we can
hypothesize that viral reservoirs, such as PMNs are recruited into the brain by the
induction of sOPN signaling from infected neurons, in the attempt to respond to
infection. However, PMN recruitment plays a negative role in neuroinvasive WNV
infection, as it traffics more virus into the brain causing increased neuroinvasive disease.
Therefore, we hypothesized that soluble OPN recruits WNV-infected PMNs into the
brain early in the course of infection, contributing to neuroinvasive WNV infection. In
brief, a better understanding for the role of sOPN within the CNS following WNV
infection can offer insight into necessary treatments that prevent neurodisease early in
infection.
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CHAPTER III – METHODS
3.1 Ethics Statement, Biosafety, and Animal Studies
All animal experimental procedures were reviewed and approved by the
Institutional Animal Care and Use Committee at The University of Southern Mississippi
(USM) (protocol # 12041201/15101601). 7-week-old, sex-matched (C57BL/6J
background) WT and Opn-/- mice (Jackson Laboratories) were intraperitoneal (i.p.)
inoculated with 2,000 plaque forming units (PFUs) of WNV (isolate CT2741) in 100 µl
of 2% gelatin in phosphate buffered saline (PBS) and mice were monitored daily up to
day 30 post infection (p.i.). Brain, spleens, and blood were collected from WT and Opn-/mice at days 2, 4, and 6 p.i. for subsequent analyses. For intracerebral (i.c.) injections of
WNV (100 PFU/mouse in 20 µl 2% gelatin) and recombinant mouse OPN (rOPN; 50
ng/mouse in 20 µl in PBS) were performed on 8-week-old, sex-matched mice
anesthetized with 30% isoflurane in isopropanol. For rOPN studies, one-hour post i.c.
rOPN supplement, i.p. inoculation with 2,000 PFU of WNV per mouse was performed
and mice were monitored up to 30 days p.i.. In additional studies, mock WT mice were
i.p. injected with high dose rOPN (200 ng/ml) 4 hr prior to blood and brain collections.
Written informed consent was obtained from all human volunteers and human
WNV cases prior to inclusion in this study. The protocol for human subject has been
reviewed and approved by the University of Southern Mississippi (USM) Institutional
Review Board (protocol # CH-R11120601). All the in vitro experiments and animal
studies involving live WNV were performed by certified personnel in the biosafety level
3 (BSL3) laboratories following standard biosafety protocols approved by the USM
Institutional Biosafety Committee.
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3.2 Cell Culture
WNV isolate (CT2741) kindly provided by John F. Anderson, was propagated
one time in Vero cells (ATCC CCL-81) and titered by using a Vero cell plaque assay, as
previously described (Paul et al., 2014). Vero cells were grown in Dulbecco’s modified
Eagle medium (DMEM) containing 1% l-glutamine (L-glu), 1% penicillin-streptomycin
(Pen/Strep) and 10% fetal bovine serum (FBS). SHSY5Y cells (ATCC CRL-2266) were
grown in Eagle’s minimal essential medium (EMEM) and F12 medium (1:1) containing
10% FBS.
Primary mixed neuronal cells were isolated from adult (6- to 12-month-old) WT
and Opn-/- mice, as previously described with some modifications (Eide & McMurray,
2005; Paul et al., 2016). Briefly, whole brains were isolated in ice-cold HEPES-buffered
saline (HBS), minced and triturated in HBS containing Papain (2 mg/ml) and incubated
for 15 minutes at 37 °C. Following incubation, cell suspensions were counted and 6 x 105
cells/ml were plated on poly-ornithine pre-treated 12-wells plates for 20 minutes at 37°C,
followed by a gentle wash with HBS to remove cellular debris. Complete media
consisting of DMEM:F12 (1:1) medium (Thermo Scientific) supplemented with 1%
Pen/Strep, 10% FBS, 1% L-glu, and glucose (4.5 g/l) was added to the cells. On day 11
of culture, supernatant was removed and replaced with neuronal feeding medium
consisting of Neurobasal®-A media (Life Technologies) supplemented with 2% B-27
(50X, Life Technologies), 10% FBS, 1% L-glu and 1% Pen/Strep and cells were infected
with WNV (MOI = 5) for 24 hrs.
Human peripheral blood mononuclear cells (PBMC) were isolated from whole
blood and isolated following Ficoll-Paque PLUS (GE Healthcare) manufactures
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instructions. Briefly, whole blood was collected in heparin-coated tubes and were diluted
into RPMI 1640 (1:4 dilution, Life Technologies) media. 15 ml of Ficoll-Paque PLUS
(GE Healthcare) was added to 50 ml conical tubes and the diluted blood was slowly
layered on top of Ficoll-Paque PLUS, followed by density gradient centrifugation at 400
xg for 40 minutes, without brake. The PBMC layer was isolated from the diluted
plasma/Ficoll interface and washed with RPMI 1640 twice, to remove any residual Ficoll
or plasma proteins. Cells were counted and plated at 1x106 cells/ml and additional
infection studies were performed.
Neutrophils were isolated from bone marrow, as previously reported (Swamydas
& Lionakis, 2013). Briefly, neutrophils were flushed from WT and Opn-/- femurs and
tibias with RPMI-1640 supplemented with 10% FBS and a 27-gauge needle. Cell were
centrifuged at 1400 rpm for 7 minutes and resuspended in 0.2% NaCl followed by 1.6%
NaCl, to lyse the red blood cells. Cells were washed with RPMI+10% FBS and were
resuspended in 1 ml of ice-cold PBS. In a 15 ml conical tube, 3 ml of Histopaque ®1119 (density: 1.119 g/ml, Sigma-Aldrich) was added, followed by a 3 ml layer of
Histopaque ®-1077 (density: 1.077 g/ml, Sigma-Aldrich) on top. PMNs were carefully
layered on top of the Histopaque layers and a density gradient centrifugation was
performed at 834 xg for 30 minutes, without brake. Following centrifugation, neutrophils
within the 1119/1077 interface (80% purity) were isolated, washed twice and
resuspended in appropriate concentrations and media for subsequent assays.
3.3 Quantitative Polymerase Chain Reaction (qPCR)
Total RNA was extracted from all cells with TRIreagent (Molecular Research
Center, Inc.) and converted into the first strand cDNA using the iSCRIPTTM cDNA
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synthesis kit (Bio-Rad). qPCR assays were performed using iTAQTM Polymerase
Supermix for probe-based assays (Bio-Rad) or iQ™ SYBR® Green Supermix
polymerase (Bio-Rad). WNV-envelope (WNV-E) gene, human OPN and mouse cellular
gene primers and probes sequences were adapted according to previous publications:
WNV-E (Town et al., 2009), OPN (Wu et al., 2012), β-Actin (Bai et al., 2005), Opn
(Chapman, 2010), Zo-1 (Yu, 2013), Claudin 5 (Hamers, 2014), Occludin (Dalessandri,
2016), Cxcl1 (Bellet, 2012), Cxcl2 (Liu, 2015), Tnf-α (Sun et al., 2016), Il-1β (Alderson,
Pearsall, Lindsay, & Wong, 1999), Il-6 (D'Angelo et al., 2017) and Icam-1 (D'Angelo et
al., 2017). Analyses were performed using either the ΔΔcT method, normalized to βActin, and represented as relative fold change (RFC) or the ratio of the absolute gene
copy number of WNV-E to β-Actin. All the primers and the WNV-E probe were
synthesized either by Integrated DNA Technologies or Applied Biosystems.
3.4 Flow Cytometry
Whole mouse brains were isolated on day 4 p.i., as previously described (Bai et
al., 2010). Briefly, whole brains were mechanically homogenized and separated into
single cell suspensions using a 70 μm cell-strainer. Infiltrating leukocytes were isolated
using Percoll gradient (70-37-30) centrifugation, followed by two washes with RPMI1640. Cells were then fixed in 2% paraformaldehyde (PFA) and resuspended in PBS
containing 2% FBS. Cells (1 × 106 cells/ml) were blocked with Fc block (5 μg/ml) in PBS
+ 2% FBS for 20 minutes at room temperature and probed with antibodies against CD45,
Ly6G, CD11b, CD4, CD8, CD19 and F4/80 and analyzed with a flow cytometer
(LSRFortessa™, BD Bioscience) using version 6.0 FACSDiva™ software (BD
Biosciences) for acquisition and analysis. All antibodies were purchased from
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eBioscience. Unstained and single-color compensation controls were used as controls.
Anti-WNV primary antibody (Abcam) and secondary anti-mouse IgG conjugated to
FITC antibody (eBioscience) were used for viral detection.
3.5 Enzyme-Linked Immunosorbent Assay (ELISA)
Levels of OPN were quantified in human and murine plasma samples by using
OPN ELISA kits (ENZO Life Sciences) following manufactures recommendations.
3.6 Evans Blue Assay
To assess blood-brain barrier integrity, WT and Opn-/- mice were i.p. infected with
2,000 PFU of WNV and on day 4 p.i., 800 µl of 2% Evans Blue dye (EBD) in PBS was
i.p. injected. One hr after EBD injection, mice were transcardially perfused with ice-cold
PBS. EBD absorbance (610 nm) in whole brain tissue was quantified using a
spectrophotometer after DMSO homogenization (Bio-Rad Smart Spec 3000TM). All
samples were normalized to control brains (with EBD, without WNV infection) for each
genotype group (WT or Opn-/-).
3.7 Neutrophil Migration Assay
PMN migration assays were performed as previously described (Koh et al., 2007)
with additional modifications. Briefly, WT and Opn-/- PMNs in RPMI-1640 were added
to inserts of transwells (3-μm pore, Corning), while RPMI-1640 with or without rOPN (2
μg/ml, R&D Systems) was added to the bottom of each well. The cells were incubated for
8 hr in a 37 °C, 5% CO2 incubator. Migrated PMNs were quantified by counting the
number of DAPI positive cells that were fixed with 4% PFA in the interface of the cells
using a confocal LSR510 microscope (Zeiss) at 63 × magnification.
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3.8 Statistical Analyses
Data were compared with a Student t test or a two-way analysis of variance with
Bonferroni post hoc analysis. Survival curves were analyzed using Kaplan-Meier
analysis. All statistical analyses were done using GraphPad Prism software (version 6.0).
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CHAPTER IV – RESULTS AND DISCUSSION
4.1 Osteopontin expression is Induced Following WNV Infection.
4.1.1 Osteopontin is Induced in Human Peripheral Blood Mononuclear Cells and
Sera from Patients Previously Exposed to WNV.
Human peripheral blood mononuclear cells (PBMC) were isolated from healthy
human volunteers without a history of WNV infection, were infected in vitro with WNV
at a multiplicity of infection (MOI) of 1 for 24 hr and the expression of Opn was
measured by quantitative real-time PCR (qPCR). The qPCR results showed that WNV
infection induced Opn expression in human PBMCs (Figure 4.1A). OPN has intracellular
and soluble forms, therefore, we sought to measure the production of secreted OPN
(sOPN) by an ELISA in a panel of human patient sera, including acute and chronic WNV
fever (WNV-F) cases, neuroinvasive acute WNV (WNV-NA) cases, and cases recovered
from neuroinvasive WNV infection WNV (WNV-NR). The ELISA results showed that
protein levels of sOPN were higher in all WNV-infected cases compared to control sera
obtained from humans with no history of WNV infection (Figure 4.1B).

Figure 4.1 Osteopontin is induced in human blood and sera following WNV infection.
(A) Human peripheral blood mononuclear cells (hPBMCs) were isolated from whole blood healthy controls (n=4) and infected with
WNV at a multiplicity of infection (MOI) 1 for 24 hours. The relative fold change (RFC) of Osteopontin (Opn) normalized to β-Actin
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was measured by qPCR. (B) Human volunteer patient sera from healthy controls (Ctrl, n=4), WNV-fever (WNV-F, n=8), WNVneuroinvasive acute infection (WNV-NA, n=8) and WNV-neuroinvasive recovered infection (WNV-NA, n=7) was collected and an
ELISA was performed to determine the expression of soluble OPN. All experiments were performed twice and analyzed using a twotailed, Student t test (* denotes p < 0.05 ± 1 SEM).

Chronic inflammation has been linked to increased OPN levels in plasma/sera
(Burdo et al., 2008; Silva et al., 2015), while increased HIV pathogenesis is dependent on
sOPN (Brown et al., 2011; Burdo et al., 2008) and patients that suffer from secondary
progressive MS have higher expression of sOPN compared to relapsing-remitting patients
(Shimizu et al., 2013). Collectively these reports suggest a role for sOPN in chronic
inflammation and possibly during inflammaging. In our studies, it is interesting to
observe increased expression of sOPN in patient samples that have recovered from
neuroinvasive WNV (WNV-NR) infection as compare to acute WNV (WNV-NA)
infection, which may contribute to increased fatigue and issues in cognition that was
observed in this cohort. In line with this, increased fatigue has been associated with
neuroinvasive WNV infection (Garcia et al., 2014) while, RRMS patients treated with
Natalizumab showed reduced sOPN levels and improved cognition and fatigue
(Iaffaldano, Ruggieri, Viterbo, Mastrapasqua, & Trojano, 2014), suggesting increased
sOPN can contribute to fatigue and cognition. Future studies include identifying
additional patient symptoms, with the goal to better delineate the role for sOPN in
recovered neuroinvasive WNV infections. In addition, it would be important to test if
there are increased levels of sOPN in WT mice that have recovered from viral infection,
and if so, assess the behavioral phenotypes observed between WT and Opn-/- mice, as this
would indicate an additional role for OPN in possible promotion of fatigue and/or
reducing cognition. In addition to fatigue, reactivation of neurological symptoms
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including paralysis and neuropathic pain were also reported in our recovered
neuroinvasive WNV infected cohort, therefore additional testing in our WT mouse model
could also delineate these pathways as well.
4.1.2 Increased Soluble Osteopontin in Mouse Plasma and Brain Homogenates
Early in WNV Infection.
To determine if sOPN was also increased following acute WNV in our murine
model, plasma and brain homogenates were collected at indicated time points post
intraperitoneal (i.p) infection with 2,000 PFU of WNV, which showed increased sOPN
levels were observed early in WNV infection in plasma and brain tissue homogenates
(Figure 4.2). Since the expression of sOPN is increased in the brain early in the course of
infection (D2 p.i.), this expression may play an important role in terms inflammation and
the “Trojan-horse” mechanism of viral infection, as sOPN can recruit PMNs to sites of its
expression (Koh et al., 2007; Sodek, Ganss, & McKee, 2000), which harbor WNV (Bai et
al., 2010). Since whole brain homogenates showed increased sOPN levels, the type of
cells that secrete sOPN following WNV in the brain is of interest. In line with this,
neurons are permissive to WNV infection and have been previously described to secrete
sOPN following other viral infections (Silva et al., 2015). In fact, neurons may be
responsible for the majority of secreted OPN in the brain (Silva et al., 2015). Therefore,
identifying the production of sOPN in neurons following WNV is necessary.
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Figure 4.2 Mouse plasma and brain homogenates secrete osteopontin early during WNV
infection.
ELISA was performed to determine the concentration of sOPN within samples on 1-day post infection (d.p.i.) in plasma (n=6) and on
1 and 2 d.p.i. in brain homogenates (n=3) post intraperitoneal (i.p.) infection with 2,000 PFU of WNV in WT mice. Ctrl denotes
uninfected WT controls. Experiments were performed twice and analyzed using a two-tailed, Student t test (* denotes p < 0.05 ± 1
SEM).

4.1.3 Neurons Secrete Osteopontin Following WNV Challenge In Vitro.
As mentioned, WNV is a neurotropic virus (Verma et al., 2009) and sOPN is
involved in the recruitment of immune cells to sites of its expression (Sodek, Ganss &
McKee, 2000), our next aim was to determine if WNV-infected neurons express OPN.
For this, human neuroblastoma cells (SH-SY5Y) and murine primary neurons were
infected with WNV (MOI = 5) for 24 hr and both Opn transcripts and sOPN were
measured by qPCR and ELISA, respectively. The results showed that Opn transcripts
(Figure 4.3A) and sOPN (Figure 4.3B) expressions were induced following WNV
infection in human and murine neuronal cells. Collectively, these results demonstrate that
permissive cells to WNV infection, including neurons produce OPN following infection,
suggesting a possible role for OPN in the pathogenesis of WNV. In addition, the
production of sOPN occurred in culture within a 24 hr time frame, suggesting rapid and
robust production of sOPN occurs following WNV infection.
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Figure 4.3 Osteopontin is induced in neurons following WNV infection.
The relative fold change (RFC) of Opn normalized to β-Actin was measured by qPCR (A) and sOPN was measured by ELISA (B), in
primary murine neurons and in a human neuronal cell line (SHSY5Y) that were infected with WNV (MOI = 5) for 24 hours. All
experiments were repeated one time and analyzed using a two-tailed, Student t test. Data represent mean ± SEM, *p < 0.05 (n=3 per
group).

4.2 Osteopontin Knockout (Opn-/-) Mice are Protected against WNV Infection.
4.2.1 Survival Curve Analysis of WT and Opn-/- Mice Following WNV Infection.
To determine the putative role of OPN in the pathogenesis of WNV in vivo, we
intraperitoneally (i.p.) infected OPN deficient (Opn-/-) mice with WNV (2,000 plaque
forming units (PFU) per mouse) and monitored morbidity and mortality daily for 30 days.
The survival results showed that nearly 70% of Opn-/- mice survived after WNV
infection, compared to approximately 30% survival of the same genetic background wildtype (WT) controls, suggesting the role for OPN in WNV infection in mice is detrimental
(Figure 4.4).
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Figure 4.4 Opn-/- mice infected with WNV have increased survival.
WT (black circles) and Opn-/- (white circles) mice were infected with 2,000 PFU / mouse of WNV (i.p.) and monitored for survival for
30 days. Survival experiments were performed three times with combined samples indicated for WT (n=22) and Opn-/- (n=31) and
analyzed using Kaplan-Meier analysis (* denotes p < 0.05 ± 1 SEM).

4.2.2 Peripheral Viremia and Immunity against WNV is No Different Between WT
and Opn-/- Mice.
To further delineate the role of OPN during WNV infection the expression of
WNV-envelope (E) (WNV-E) in blood and tissues was measured by qPCR, which
indicated comparable viral load in blood and spleens between WT and Opn-/- mice at D2
and D4 p.i. (Figure 4.5A and 4.5B). Since OPN has been suggested to regulate type I
interferon production (Cao & Liu, 2006; Zhao et al., 2016), we measured expression of
Ifn-β by qPCR in spleens, which was not significantly different between WT and Opn-/mice at D2, D4 and D6 p.i. (Figure 4.5C). Additional cytokines were also analyzed to
determine if OPN contributed to induction of key proinflammatory cytokines involved in
innate immunity, however, there was no significant difference between WT and Opn-/mice splenocytes with Il-6 and Tnf-α (Figure 4.5C). Since proinflammatory genes Tnf-α
or Il-6 have been implicated in disruption of the BBB (Zhang et al., 2015), (Franceschi &
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Campisi, 2014) and no significant differences were observed with these cytokines we can
conclude that OPN expression does not directly enhance antiviral or proinflammatory
immunity against WNV in the periphery.

Figure 4.5 WT and Opn-/- mice infected with WNV display no difference in viremia.
WT (black circles) and Opn-/- (white circles) mice were infected with 2,000 PFU / mouse of WNV (i.p.) blood (A) and spleens (B)
were collected on D2 and D4 p.i. and WNV-E and cellular β-actin were measured by qPCR and plotted as log10 (RNA expression)
(n=16-22). (C) Spleens were collected at 2, 4 and 6 days post infection (d.p.i.) and qPCR was performed to measure Ifn-β, Il-6, and
Tnf-αnormalized to β-actin. Data are presented as relative fold change (RFC) with WT-infected controls set at 1 (horizontal, dotted
line) and Opn-/- mice data is depicted in white bars. All experiments were performed twice and analyzed using a two-tailed, Student t
test (* denotes p < 0.05 ± 1 SEM).

4.2.3 Brain Tissue Isolated from Opn-/- Mice Display Reduced Viral Load.
In contrast to peripheral blood and tissue, viral burden in the brain tissues of Opn/-

mice was significantly lower than in WT control mice at D4 and D6 p.i., while WNV

RNA was minimally detected in brain tissues collected on D2 p.i. (Figure 4.6). These
results suggest that WNV can enter WT and Opn-/- mice brain parenchyma at the same
rate (D2), however following WNV establishment in the brain, viral load increased
significantly in WT mice that was not present in Opn-/- mice brains (D4 and D6).
Therefore, two scenarios are possible in Opn-/- mice; one, Opn-/- brains are more resistant
to viral infection, or two, defective entry of additional virus occurs in Opn-/- mice brains.
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In brief, viral burden in brain tissues agree with the survival results (Figure 4.4),
suggesting that OPN may contribute to WNV neurodisease by enhancing infection in the
brain.

Figure 4.6 Opn-/- mice infected with WNV have reduced viral burden in brain tissue.
WT (black circles) and Opn-/- (white circles) mice were infected with 2,000 PFU / mouse of WNV (i.p.) and WNV-E and cellular βactin were measured in brain tissue by qPCR and plotted as log10 (RNA expression) (n=4-36) at selected time points post infection
(p.i.). Experiments were performed twice and analyzed using a two-tailed, Student t test (* denotes p < 0.05 ± 1 SEM).

4.2.4 Opn-/- Brain Tissues Display Reduced Icam-1, but No Difference in
Proinflammatory or Antiviral Gene Expression Early in WNV Infection.
To determine the antiviral and inflammatory response with the brain following
WNV between WT and Opn-/- mice, brains were collected on days 2 and 4 p.i. following
infection with 2,000 PFU of WNV i.p.. The qPCR results showed that there are no
significant differences between WT and Opn-/- mice proinflammatory gene expression,
including Tnf-α, Il-1β, Il-6 and antiviral gene Ifn-β early in disease (D2 and D4 p.i.)
(Figure 4.7). Both Tnf-α, Il-1β, and Il-6 have been shown to contribute to BBB disruption
(Franceschi & Campisi, 2014; Zhang et al., 2015) however, these cytokines are not
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increased in WNV-infected Opn-/- mice early after WNV establishment in the brain (D2),
suggesting these cytokines do not contribute to BBB permeability in Opn-/- mice.
Interestingly, Icam-1 (intracellular adhesion molecule-1) an endothelial cell marker
involved in leukocyte extravasation, was reduced on D2 p.i., but was no different on D4
p.i. (Figure 4.7), suggesting reduced leukocyte infiltration may also be inhibited early in
viral infection (D2) in Opn-/- mice, but is not dependent on ICAM-1 expression alone. In
line with this, Icam-1 expression is dependent on inflammatory mediators (Wung, Ni, &
Wang, 2005). Therefore, we propose since major proinflammatory genes Tnf-α, Il-1β and
Il-6 are no different between WT and Opn-/- mice reduced OPN expression may be the
primary contributor to reduced Icam-1 expression that is observed early in infection of
Opn-/- mice brains, which may affect leukocyte extravasation into the brain parenchyma.

Figure 4.7 Brain tissue isolated from Opn-/- mice display no significant difference in
proinflammatory and antiviral gene expression early in WNV infection.
WT and Opn-/- mice (white bars) brains were collected as indicated days post infection (d.p.i.) and qPCR for Tnf-α, Il-1β, Il-6, Ifn-β
and Icam-1 normalized to β-Actin was performed. Data are expressed as relative fold change (RFC) with WT-infected controls set at 1
(horizontal, dotted line, n=4-12). Experiments were performed two times and analyzed using a two-tailed, Student t test (* denotes p <
0.05 ± 1 SEM).
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4.2.5 Opn-/- Mice Lack Brain-Intrinsic Antiviral Function Against WNV.
To determine if brain-intrinsic antiviral immunity was involved in Opn-/- mice, we
directly injected 100 PFU of WNV into the brains of Opn-/- and WT control mice via an
intracerebral (i.c) inoculation route, and brain tissue was collected on day 6 (D6) p.i. to
measure viral burden by qPCR (Figure 4.8). The results showed increased WNV RNA in
the brains of Opn-/- mice compared to WT controls, which excludes the possibility that
brain tissue of Opn-/- mice might be resistant to WNV. In fact, these results describe just
the opposite, as there is significantly more virus in Opn-/- brains following direct
inoculation into the brain parenchyma. Therefore, providing additional insight into the
pathogenesis of WNV and the importance of a cohesive BBB. Since peripheral infection
in Opn-/- mice results in reduced viral load in the brain, while i.c. infection results in
increased viral load in the brain, there must be a defect in trafficking of virus into the
brain. In addition, the integrity of the BBB following viral infection may be tighter in
Opn-/- mice, which can inhibit the Trojan horse mechanism of viral entry. In brief, these
results suggested that OPN might facilitate WNV brain invasion in mice.

Figure 4.8 Intracerebral WNV infection results in increased viral burden in Opn-/- mice
brains.
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The ratio of WNV-E to β-actin in brain was determined by qPCR and plotted as log10 (RNA expression) in WT (black circles, n=8)
and Opn-/- (white circles, n=11) mice following intracerebral (i.c.) infection with 100 PFU of WNV per mouse. Experiments were
performed twice and analyzed using a two-tailed, Student t test (* denotes p < 0.05 ± 1 SEM).

4.3 Opn-/- Mice Have Uncompromised Blood-Brain Barriers (BBB) Following WNV
Infection, While Osteopontin Supplement Does Not Affect BBB Integrity.
4.3.1 Opn-/- Mice Have Tighter BBB Following WNV Infection.
The blood-brain barrier (BBB) is an important physiological barrier for protecting
the brain against various insults, including WNV and other neuroinvasive pathogens
(Dahm, 2016; Verma et al., 2009). Since we found a similar level of viremia, in Opn-/and WT mice following i.p. infection (Figure 4.5), but Opn-/- mice displayed a lower viral
burden in brain tissue (Figure 4.6) that was not due to intrinsic Opn-/- brain tissue
resistance (Figure 4.8), we next sought to determine if the BBB is tighter in Opn-/- mice
than WT mice following WNV infection. We used an Evans blue assay to determine the
permeability of the BBB and found that Opn-/- mice had reduced Evans blue dye
integration in their brain tissues as compared to WT controls, suggesting that Opn-/- mice
have a tighter BBB following WNV infection (Figure 4.9). In comparison to uninfected
controls that displayed no difference in Evans blue absorbance, only upon WNV
infection does the BBB become compromised. Moreover, inhibition of Evans blue dye in
Opn-/- mice brain parenchyma following infection indicates that there may be reduced
neuronal damage associated with WNV infection in these mice.
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Figure 4.9 Opn-/- mice have reduced Evans blue dye integration in brain parenchyma.
WT (black circles, n=21) and Opn-/- (white circles, n=27) mice were infected with WNV (2,000 PFU i.p.) and mock WT (black
circles, n=12) and Opn-/- (white circles, n=15) treated (PBS i.p., 100 μl) mice were used as absorbance controls. (Left panel) Brain
infiltrated Evans blue dye was measured with a spectrometer (610 nm) on day 4 p.i.. (Right panel) Visual representation of brain
tissues post-Evans blue injections. Experiments were performed twice and analyzed using a two-tailed, Student t test (* denotes p <
0.05 ± 1 SEM).

4.3.2 Opn-/- Mice Have Increased Expression of Tight Junction Genes Following
WNV Infection.
To further confirm Opn-/- mice have a tighter BBB, we evaluated the expression
of BBB tight junction-related genes Zo-1, Claudin 5 and Occludin and found that the
expression of Zo-1 and Claudin 5 were significantly higher in brain tissue of Opn-/- mice
on D4 p.i. (Figure 4.10). These results further highlight the importance of leukocyte
extravasation during neuroinvasive WNV infection, since changes in tight gene
expression were only observed at a time point when leukocyte extravasation is active (D4
p.i.), with no difference in tight junction gene expression at the time of initial viral entry
into the brain (D2 p.i.) (Figure 4.10). Therefore, increased % of leukocytes carrying
WNV into the brain may be a major contributor to neuroinvasive WNV infection. These
results collectively suggest that Opn-/- mice are protected from BBB damage-associated
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with WNV infection that occurs in WT brains, and further confirmed that Opn-/- mice
have a tighter BBB than WT mice following WNV infection.

Figure 4.10 Opn-/- mice have tighter blood brain barriers.
Relative fold change (RFC) of tight junction marker genes Zo-1, Claudin 5 and Occludin normalized to β-actin were measured in
brains on 2, 4, and 6 days post infection (d.p.i) by qPCR (n=4-6). The horizontal dotted line represents WT-infected controls at each
time point set as 1 and Opn-/- mice data is depicted in white bars. All experiments were performed twice and analyzed using a twotailed, Student t test (* denotes p < 0.05 ± 1 SEM).

Since WT mice have increased BBB compromise as compared to Opn-/- mice
(Figure 4.9), but do not display difference in proinflammatory mediator expression at
similar time points (D4) (Figure 4.7) following infection, we sought to determine if in the
absence of WNV infection, overexpressed OPN could disrupt the integrity of the BBB
directly or possibly induce proinflammatory mediators including Tnf-α, Il-6, and Il-1β
that can cause BBB compromise (Franceschi & Campisi, 2014; Kempuraj et al., 2016;
Zhang et al., 2015).
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4.3.3 Increased Osteopontin Does Not Induce Proinflammatory Cytokines or Inhibit
BBB Tight Junction Gene Expression in Uninfected Mice.
BBB compromise is a result of heightened inflammation, via increased expression
of Tnf-α, Il-6, and Il-1β (Franceschi & Campisi, 2014; Kempuraj et al., 2016; Zhang et
al., 2015). While Opn-/- mice had tighter BBB (Figure 4.9) and increased tight junction
gene expression (Figure 4.10) during infection, it is not known if OPN directly caused
BBB compromise. Therefore, in the absence of infection, high-dose OPN (rOPN, 200
ng/ml) was supplemented into WT mice for 4 hr via i.p. injection to determine if
overexpressed OPN, in the absence of infection, contributed to BBB compromise. High
dose concentration of rOPN was determined by comparing plasma sOPN concentrations
that were well above levels observed in WNV infected mice (Figure 4.2), indicating a
possible pathophysiological concentration of OPN. Blood was collected and qPCR
analyzed for expression of proinflammatory genes Tnf-α, Il-6 and Il-1β (Figure 4.11A),
which indicated no difference in inflammation following rOPN treatment. To determine
if high levels of OPN can affect the BBB compromise directly, brain tissues were also
collected 4 hr post treatment and qPCR analyzed for the expression of BBB tight junction
genes Zo-1, Claudin 5 and Occludin (Figure 4.11B). The results indicate that at this time
point of blood and tissue collection, supplementing high dose concentrations of rOPN to
uninfected WT mice does not induce a pro-inflammatory response or directly contributes
to BBB compromise. Moreover, these results highlight the important contribution of
active leukocyte extravasation (carrying virus) into the brain, being a principle
mechanism of WNV neuroinvasive infection.
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Figure 4.11 Recombinant osteopontin supplement in uninfected mice does not result in
inflammation or blood-brain barrier compromise.
WT uninfected mice were i.p. treated with high dose rOPN (200 ng/ml) (black bars) or PBS (dotted line) as a vehicle control.
Proinflammatory gene expression in blood for Tnf-α, Il-6 and Il-1β (A) and brain tight junction markers Zo-1, Claudin 5 and Occludin
(B) were measured by qPCR 4 hr post-treatment. PBS vehicle controls are set at 1 (horizontal, dotted line) and all data were
normalized to β-Actin and expressed as relative fold change (RFC). Experiment was performed one time (n=3 mice per group) and
analyzed using a two-tailed, Student t test (* denotes p < 0.05 ± 1 SEM).

4.4 Viral Resistance in Opn-/- Mice is Dependent On Reduced Polymorphonuclear
Neutrophil (PMN) Brain Infiltration.
4.4.1 PMNs are Primary Carriers of WNV into the Brain during Neuroinvasive
Infection in Mice.
To alluded to the importance of leukocyte extravasation contributing to
neuroinvasive WNV infection and to determine the principle cell type that contributes to
neuroinvasive trafficking of the virus into the brain. Total leukocytes isolated from WTinfected mice (i.p. 2,000 PFU) on day 4 p.i. were profiled, as previous studies have
identified PMN-infiltration into the brain following WNV infection at this time point
(Brehin et al., 2008). The results showed that approximately 80% of
Ly6G+CD11b+/CD45high (PMNs) harbored WNV, as compared to other brain-infiltrating
leukocytes including CD4+/CD45high (~20%), CD8+/CD45high (~30%), CD19+/CD45high
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(~5%) and LY6G-CD11b+/CD45high (myeloid cells, ~40%) (Figure 4.12). Therefore,
PMN are the most permissive leukocyte to WNV infection and are the primary vehicles
for WNV delivery into the brain during neuroinvasive infection.

Figure 4.12 WNV infected brain-infiltrating leukocyte populations during WNV
neuroinvasion.
WT mice were i.p. infected with 2,000 PFU of WNV and brains were collected on D4 p.i. for flow cytometric profiling of braininfiltrated leukocyte populations that harbored WNV (% WNV). Subpopulations were gated within total CD45high brain infiltrating
cells. Experiment was performed twice (n=3 mice per group).

4.4.2 Opn-/- Mice Have Reduced PMN Brain Infiltration Following WNV Infection.
To further investigate the mechanism by which OPN contributes to WNVneuroinvasion, we used flow cytometry to examine immune cell infiltration following
WNV infection. Since immune cells can play a dual role, either limiting or facilitating
pathogenicity during WNV infection (Bai et al., 2010; Drescher & Bai, 2013), we
isolated and profiled the brain infiltrating immune cells in WNV-infected (2,000
PFU/mouse i.p) WT and Opn-/- mice on day 4 p.i. by flow cytometry. The results showed
Opn-/- mice had similar level of brain-infiltrating leukocytes (CD45high), CD4+ cells
(CD4+/CD45high) and myeloid (Ly6G-CD11b+/CD45high) cells, while slightly increased B54

lymphocytes (CD19+/CD45high) and CD8+ cells (CD8+/CD45high) were observed, along
with significantly reduced PMNs (Ly6G+CD11b+/CD45high). These results identified
PMNs as the major cell type that was reduced (~10%) compared to WT controls in Opn-/brains following WNV infection (Figure 4.13), and since PMNs have been previously
identified to harbor WNV into the brain (Bai et al., 2010) (Figure 4.12), these cell types
are an attractive cell to study. To further identify the contribution of OPN during PMNWNV neuroinvasion, we next examined PMN recruitment and viral permissiveness
compared to WT controls.

Figure 4.13 Opn-/- mice have reduced PMN brain infiltration following WNV infection.
WT (black bars) and Opn-/- (white bars) mice were infected with 2,000 PFU (i.p.). (Top panel) Brain-infiltrating leukocytes were
quantified by flow cytometry on day 4 p.i., including total infiltrating leukocytes (CD45 high), CD4+ cells (CD4+/CD45high), CD8+ cells
(CD8+/CD45high), B cells (CD19+/CD45high), PMNs (Ly6G+CD11b+/CD45high) and myeloid cells (Ly6G-Cd11b+/CD45high); n=4-6 mice
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per group. (Bottom panel) Representative flow cytometric plots for used in gating of subpopulations. Experiments were performed
twice and analyzed using a two-tailed, Student t test (* denotes p < 0.05 ± 1 SEM).

4.4.3 Opn-/- Mice Have Reduced PMN-Specific Chemokine Expression Following
WNV Infection.
Since chemokines are responsible for PMN recruitment (Kobayashi, 2008), we
next measured expression of chemokines in the brain tissue of WT and Opn-/- mice and
found that the expression of the two major PMN chemoattractant genes Cxcl1 and Cxcl2
were significantly reduced in Opn-/- mice brain tissue compared to WT mice (Figure
4.14), which may be attributed to less viral infection in the brain of Opn-/- mice (Figure
4.6). Interestingly, the reduction of PMN chemokines did not gain significance until D6
p.i., while reduced brain-infiltrating PMNs were observed before this time point at D4 p.i.
(Figure 4.13), suggesting other recruitment molecules are probable early in infection, i.e.,
sOPN. Collectively, these results suggest that while reduced expression of PMN-specific
chemokines may contribute to reduced PMN brain infiltration later during the course of
infection (D6 p.i.), PMN infiltration in the brains earlier in infection (i.e. D2-4) may be
more dependent on sOPN chemotactic properties.

Figure 4.14 Opn-/- mice have reduced PMN-specific chemokine expression profiles in the
brain following WNV infection.
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WT (dotted line) and Opn-/- (white bars) mice (n=4-6) were infected with 2,000 PFU (i.p.) and whole brains were collected and
subjected to qPCR on 2, 4 and 6 days post infection (d.p.i.). Relative fold change (RFC) of Cxcl1 and Cxcl2 normalized to β-actin,
with WT-infected controls set at 1 (horizontal, dotted line). Experiments were performed twice and analyzed using a two-tailed,
Student t test (* denotes p < 0.05 ± 1 SEM).

4.5 Soluble Osteopontin Directly Recruits PMNs, While WT and Opn-/- PMNs
Display Similar Viral Permissiveness.
4.5.1 PMNs Can Migrate to Sites of Osteopontin Expression.
Since reduced PMN infiltration was observed in brains of Opn-/- mice (Figure
4.13) and OPN has been shown to recruit PMNs in vitro (Koh et al., 2007), and we also
wanted to confirm that recombinant OPN (rOPN) could attract PMNs in a transwell
migration assay (Figure 4.15). For this, rOPN (2 μg/ml) was added to the bottom
chamber with bone marrow derived PMNs added to the top chamber of a transwell plate,
and cells were incubated for 8 hr. Following incubation, the top layer of PMNs were
removed and the interphase layer of the transwell chamber was fixed and counted to
determine the number of migrating PMNs, as previously described (Koh et al., 2007).
These results confirmed that along with reduced expression of Cxcl1 and Cxcl2
chemokine expression (Figure 4.14), reduced PMN infiltration in brains of Opn-/- mice
might be due to lack of sOPN.
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Figure 4.15 Recombinant osteopontin recruits PMNs in vitro.
A transwell migration assay using bone marrow derived PMNs isolated from WT mice (black bar) with recombinant mouse OPN
(white bar, rOPN, 2 μg/ml), n=3 per group. Experiments were performed twice and analyzed using a two-tailed, Student t test (*
denotes p < 0.05 ± 1 SEM).

4.5.2 WT and Opn-/- PMNs are Equally Permissive to WNV Infection.
As reduced PMNs were observed in Opn-/- mice brains following infection
(Figure 4.13) and PMNs can harbor WNV (Figure 4.12), it was important to describe if
PMNs from WT and Opn-/- had similar permissiveness to WNV infection. Along with our
results (Figure 4.12), previous studies have demonstrated that PMNs are very permissive
to WNV infection and could facilitate WNV invasion into the brain (Bai et al., 2010;
Wang, Zenewicz, Dai, Gate, Cheng, Yang, Qian, Yuan, Montgomery, Flavell, Town,
Fikrig, 2012). Therefore, to determine if deficiency of OPN affects the permissiveness of
PMNs to WNV, we compared WNV replication in bone marrow-derived PMNs from WT
and Opn-/- mice by qPCR (Figure 4.16). The results indicated that PMNs from Opn-/mice are similarly permissive to WNV infection compared to WT PMNs, which suggests
although there is defective recruitment into the brain following WNV in Opn-/- mice,
Opn-/- PMNs display similar viral permissiveness to WNV. These results further suggest
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similar antiviral function between WT and Opn-/- PMNs. Therefore, we hypothesized that
the primary role for sOPN following WNV infection is to recruit PMNs into brain, which
act as viral reservoirs, paradoxically enhancing WNV neuroinvasion.

Figure 4.16 WT and Opn-/- PMNs are similarly permissive to WNV infection.
Bone-marrow derived PMNs from WT (black bars) and Opn-/- (white bars) mice (n=4 per group) were infected in vitro with WNV at a
multiplicity of infection (MOI) of 0.1, 1 and 10 for 24 hr, followed by qPCR analysis to measure WNV-E relative to β-Actin and
plotted as log10 (RNA expression). Experiments were performed twice and analyzed using a two-tailed, Student t test (* denotes p <
0.05 ± 1 SEM).

4.6 Intracerebral Treatment With Recombinant Osteopontin (rOPN) Results in
Increased Morbidity in Opn-/- Mice.
4.6.1 Intracerebral Treatment of rOPN in Opn-/- Results in Increased PMN
Infiltration into the Brain Parenchyma Following WNV Infection.
Since sOPN can recruit PMNs in vitro, to test this in vivo, we injected rOPN (50
ng in 20 μl / mouse, i.c.), or an equal volume of PBS as a vehicle control, into the brains
of Opn-/- mice and 1 hr later infected them with WNV (2,000 PFU, i.p.). The mice were
euthanized and their brains were isolated on D4 p.i., a time point when the BBB was
compromised, as indicated by Evans blue BBB permeability assay (Figure 4.9). The
results showed that that infiltrated PMN population (Ly6G+CD11b+/CD45high) were
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significantly increased following rOPN supplement in Opn-/- mice brains, while the
infiltration of CD4+ cells, CD8+ cells and macrophage populations (F4/80+) were not
significantly altered (Figure 4.17), suggesting that rOPN can selectively recruit PMNs
into brain following WNV infection.

Figure 4.17 Intracerebral recombinant osteopontin supplement recruits PMNs in Opn-/mice.
Opn-/- mice were pretreated with rOPN (squares, 50 ng, i.c.) or PBS (circles, as a vehicle control) and 1 hr later were infected with
WNV (2,000 PFU, i.p.). Brain-infiltrating leukocytes (n=7-16) were quantified by flow cytometry on day 4 p.i.; CD4+ cells
(CD4+/CD45high), CD8+ cells (CD8+/CD45high), macrophages (F4/80+/CD45high) and PMNs (Ly6G+CD11b+/CD45high). Experiments
were performed three times and analyzed using a two-tailed, Student t test (* denotes p < 0.05 ± 1 SEM).

In addition, i.c. injection with PBS in Opn-/- mice resulted in slightly increased
infiltrating populations of CD8+ cells (~35%) and PMNs (~15%) into the brain (Figure
4.17), compared to Opn-/- mice without i.c. PBS injections (CD8+ cells (~18%) and
PMNs (~4%), Figure 4.13), indicating that direct brain parenchyma disruption, via i.c.
PBS injections, contributes to recruitment of leukocytes, suggesting immune cell braininfiltration is in response to direct brain insult. In line with this, it has been shown that
following brain infarction there is increased brain leukocyte infiltration, including PMNs
and CD8+ T cells (Gronberg, Johansen, Kristiansen, & Hasseldam, 2013), while %
infiltration was dependent on the time of occlusion, whereby PMNs peaked early in the
brain (D1-2) following long-term occlusion (120 min), resulting in death versus short60

term occlusion (30 min time, D3 peak infiltration) (Gronberg et al., 2013). Although
models for stroke and WNV are different, their relationship with immune cell infiltration
causing brain disruption is recognized between the two. Therefore, a better understanding
of the population kinetics of leukocyte infiltration into the brain parenchyma following
WNV neuroinvasion, are of interest as well.
4.6.2 rOPN-Treated Opn-/- Mice Have Increased Viral Load in Brain Parenchyma.
While increased PMNs were observed in rOPN-treated Opn-/- mice brain (Figure
4.17), and PMNs can harbor WNV (Figure 4.12), the viral burden in brain tissue of PBSand rOPN-treated Opn-/- mice was measured. In complement with the PMN-infiltration
results (Figure 4.13), we found that i.c. rOPN supplemented into Opn-/- mice resulted in
increased viral burden as compared to i.c. PBS-supplemented mice (Figure 4.18),
suggesting sOPN recruits WNV-infected PMNs into the brain and further identifies OPN
as an important contributor to neuroinvasive WNV disease.

Figure 4.18 Intracerebral recombinant osteopontin supplement in Opn-/- mice results in
increased viral burden in brain tissues.
Opn-/- mice were pretreated with PBS (white bars) or rOPN (black bars, 50 ng, i.c.) and were infected 1 hr later with WNV (2,000 PFU
i.p.). Brains (n=4 per group) were collected on day 4 p.i. and a qPCR of WNV-E gene to β-actin was performed and plotted as log10
(RNA expression). Experiments were performed three times and analyzed using a two-tailed, Student t test (* denotes p < 0.05 ± 1
SEM).
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4.6.3 rOPN-treated Opn-/- Mice Have Increased Morbidity Following WNV
Infection.
As mentioned, increased viral load is associated with neuroinvasive disease
(Diamond et al., 2003), therefore to determine if increased WNV burden in the brains of
rOPN-supplemented Opn-/- mice (Figure 4.18) resulted in increased neuroinvasive
disease survival tests were performed, which showed dramatically reduced survival in
Opn-/- mice supplemented with rOPN compared to Opn-/- mice supplemented with PBS
(Figure 4.19). In fact, rOPN supplemented Opn-/- mice closely resembled the survival
curve of WT mice (~30% survival, Figure 4.4 compared to ~40% survival Figure 4.19).
In addition, death of WT mice occurred between days 9-14 (Figure 4.4), while rOPN
treated Opn-/- mice death occurred between days 9-12 (Figure 4.19), suggesting similar
PMN kinetics in neuroinvasive disease between these two groups. Collectively, these
results confirmed that sOPN could recruit WNV-infected PMNs into the brain,
facilitating WNV neuroinvasive disease.

Figure 4.19 Intracerebral recombinant osteopontin supplement in Opn-/- mice results in
reduced survival.
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Survival of 8-week-old Opn-/- mice either pretreated i.c. with rOPN (black circles, 50 ng/mouse n=21) or PBS (white circles, n=16) for
1 hr, followed by i.p. infection with 2,000 PFU of WNV and were monitored for 30 days p.i.. Experiments were performed three times
and analyzed using Kaplan-Meier analysis (* denotes p < 0.05 ± 1 SEM).
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CHAPTER V – CONCLUSIONS AND FUTURE DIRECTIONS
This study has identified that OPN promotes neuroinvasion in a mouse model of
WNV infection. More specifically, Opn-/- mice in comparison to WT mice have more
than twice the higher rate of survival after WNV infection, which was associated with a
tighter BBB, decreased PMN infiltration and reduced viral burden in the CNS early in the
time course of infection. To confirm the effects of OPN on WNV neuroinvasive disease,
supplementing recombinant OPN into brains of Opn-/- mice enhanced WNV
neuroinvasion, complementary to WT infection. The overall findings support the
hypothesis that OPN promotes WNV neuroinvasion via a ‘Trojan-horse’ mechanism of
viral CNS entry (Verma et al., 2009) through recruitment of WNV-infected PMNs into
the CNS, enhancing disease severity.
In this study, the mouse immune system and the innate immune mediator OPN
was thoroughly analyzed to determine if this protein could be involved in neuroinvasive
WNV infection. Understanding the role of OPN, and its contribution to neuroinvasive
WNV offered some additional insight into the pathogenesis of neuroinvasive WNV in
mice. For instance, soluble OPN acts as a chemokine to attract PMNs into the brain
following infection. This study identified WNV must first establish itself in the brain,
through an unknown mechanism of viral entry, prior to triggering a specific brainintrinsic inflammatory cascade and recruitment of leukocytes to clear infection.
Paradoxically, in Opn-/- mice following WNV infection there was reduced recruitment of
a specific immune cell type referred to as PMNs, early in disease (D4). While no
additional brain collections were made post D4, we suspect later in disease course (D6D8) additional immune mechanisms would develop to clear the virus. Therefore, future
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studies could identify the subpopulations of brain-infiltrating leukocytes between WT and
Opn-/- mice that occur later in disease progression. For instance, CD8+ T cells (Shrestha
& Diamond, 2004) and PMNs (Bai et al., 2010) also contribute to viral clearance later
during infection and therefore, these additional studies may provide insight into the viral
resistance that is displayed in Opn-/- mice.
Additionally, the inflammatory response is a complex pathway that is triggered in
response to infection or injury in order to commit to controlling foreign challenge, yet
overt inflammation has contributed of many brain-related pathologies (Franceschi &
Campisi, 2014). Therefore, in the brain, the timing, propensity, and resolve of
inflammation is critical to prevent neurodegeneration. Following WNV infection in Opn-/mice there was no difference in inflammatory mediator gene expression Tnf-α, Il-1β, and
Il-6, however, these are just three of a wide variety of inflammatory mediators that
contribute to inflammation, including molecules such as IL-12 and nitric oxide, to name a
few. Therefore, future directions for this project would be to run a microarray on the
brain tissue isolated from WT and Opn-/- mice, at different time points p.i. to identify the
immune profiles and inflammatory mediators against WNV that are altered between these
two groups, which may aid in a better understanding of the host immune kinetics against
the virus.
Interestingly, Icam-1 was reduced in Opn-/- mice compared to WT controls at D2
p.i., which suggests reduced inflammation and antiviral immunity may have contributed
to reduced Icam-1 expression, as its expression is induced by NFκB and STATs (Wung et
al., 2005), following inflammation. Since ICAM-1 has been implicated to facilitate WNV
entry into the brain (Dai, Wang, Bai, Town, & Fikrig, 2008), identifying the mechanism
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for Icam-1 expression is of great interest in the Trojan horse mechanism of viral entry
and neuropathogenesis, which requires further studies. Additional other endothelial
receptors such as selectins also require attention, as their expression is also inflammationdependent and participate in leukocyte extravasation. In line with leukocyte
extravasation, PMN activation prior to binding to endothelial cells requires a
conformational change in their cell surface integrins. Interestingly, sOPN binds to
integrins and this interaction may aid leukocyte migration into brain parenchyma. Indeed
this has been previously described with embryo implantation into the endometrium
(Kang, Forbes, Carver, & Aplin, 2014). In addition, while OPN can also bind to an
additional receptor called CD44v6, which enables cell survival. This mechanism has been
previously characterized in various cancer models (Lee et al., 2007; Maeda et al., 2015).
In line with our studies, CD44v6 is expressed on PMNs and binding of OPN to this
receptor may promote PMN survival, which is of interest in terms of viral hijacking of
immune cells and viral dependence on the host cell for survival. It would be interesting to
look at the survival kinetics of WNV-infected PMN in the presence or absence of rOPN,
to determine if OPN contributes to PMN survival, which could contribute to the Trojan
horse mechanism of WNV neuroinvasion.
Furthermore, the induction of tight junction molecules in Opn-/- mice is still an
open question that requires further studies. To address this in future studies, nitric oxide
and MMP-9 has been shown to be major contributors to tight junction protein cleavage
(Roe et al., 2012), and therefore additional studies into the expression of these proteins,
or other mediators that are devoid in Opn-/- immunity is essential. Additional protein
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assays, such as immunohistochemistry of tight junction protein expression between WT
and Opn-/- brain tissue could contribute to these studies as well.
While OPN may be an attractive target for therapeutic intervention of disease
development, practicality of designing a therapeutic to target this protein is complex.
Following infection of neurons, sOPN is highly upregulated and is then secreted out of
the brain into blood circulation to recruit PMNs. However, inhibiting sOPN with antiOPN antibodies or specifically designed drugs may be difficult since large molecules
cannot pass the BBB. In addition, targeting sOPN and or PMNs during the course of
infection must be carefully timed and varies from patient to patient depending on the time
course of WNV dissemination into the brain. This is critical since PMNs serve to carry
the virus early in infection and clear the virus later during infection (Bai et al., 2010),
suggesting intervention targeting sOPN must be done early in viral establishment, which
must be standardized in humans. The same holds true for other therapeutic design, for
example, PMNs can enter the brain parenchyma in response to infection through binding
to endothelial receptors, such as ICAM-1, and reduced Icam-1 in brains of Opn-/- early in
disease, may have contributed to reduced overall immune cell extravasation into the brain
parenchyma. Therefore, blocking leukocyte adhesion receptors early in disease
progression may prevent the Trojan horse mechanism of neuroviral infection. However,
this blockage must be reversible and performed very early following infection
establishment to prevent the Trojan horse entry of infected leukocytes, but as mentioned
above, inhibiting immune cell infiltration in the brain later during infection may
contribute to disease progression (Bai et al., 2010).
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In summary, OPN has been implicated in many pathological conditions in humans
and this study has identified its role during neuroinvasive WNV infection in mice. While
offering insight into the mechanism of neuroinvasive WNV infection, to translate these
studies to humans, it is imperative to determine if PMNs indeed act as Trojan horse
vehicles for viral delivery into the brain. Although neutrophilia has been associated with
neurocognitive impairment in human WNV infection (Crichlow et al., 2004; Tyler et al.,
2006), the contribution of these cells as viral carries in humans is still an open question.
Nonetheless, this study successfully identified PMNs as principle cells involved in viral
hijacking and Trojan horse transmigration into the brain parenchyma in mice and the role
for OPN in this process. In brief, if sOPN or PMNs are inhibited early during viral
pathogenesis, a better prognosis for viral-induced neurodisease may be possible.
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